FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the period from January 1, 2003
to November 17, 2003

Lorus Therapeutics Inc.

(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

[Indicate by check mark whether the
registrant files or will file annual reports
under cover Form 20-F or Form 40-F.]

Form 20-F ___ ____ Form 40-F __ X__

[Indicate by check mark whether the registrant by
furnishing the information contained in this Form is also
thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.

Yes _____ No ____X___

[If "Yes" is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: November 19, 2003

By: "Shane Ellis"

Shane Ellis
Vice President,Legal Affairs
Corporate Secretary

Index for the 6-K filing

99.1 Press release: Appointment of Robert Capizzi to Lorus Board

99.2 Press release: Various staff change announcement

99.3 Press release: Lorus presents research findings at ONCOGENE meeting

99.4 Press release: US NCI clinical development for GTI-2040

99.5 Press release: Lorus allowed Mexico patent to protect Virulizin

99.6 Press release: Lorus presents Virulizin at InCan meeting in Mexico

99.7 Press release: FDA grants Orphan drug Status to GTI-2040 on Renal Cell Carcinoma

99.8 Press release: Q203 results announcement

99.9 Press release: Lorus to advance GTI-2501 into phase II

99.10 Press release: Lorus publishes results of Virulizin in peer reviewed journal

99.11 Press release: Lorus announces US patent allowance on Virulizin

99.12 Press release: Lorus allowed Canadian patent on Antimicrobial drugs

99.13 Press release: Q303 results announcement

99.14 Press release: Lorus announces progress with phase III Virulizin trial

99.15 Press release: Lorus announces scientific publication that expand the application of Virulizin

99.16 Press release: Lorus publishes results of GTI-2040 against broad range indications

99.17 Press release: Lorus announces Virulizin presentation at Lustgarden conference

99.18 Press release: Lorus reports year end results of fiscal 2003

99.19 Press release: Lorus announces the initiation of the 3rd clinical trial with US NCI

99.20 Press release: Lorus announces presenting at a Gene Therapy conference

99.21 Press release: Lorus announces presenting at the Biopartnering in Europe

99.22 Press release: Lorus announces the publication of Virulizin mechanism of Action Study

99.23 Press release: Lorus sponsors Lung Cancer meeting

99.24 Press release: Lorus closes financing

99.25 Press release: Lorus files final prospectus

99.26 Press release: Lorus files preliminary short-form prospectus

99.27 Press release: Lorus allowed US Thiodoxin Reductase patent

99.28 Press release: Lorus allowed US patent on antisense anticancer target

99.29 Press release: Lorus allowed US Antimicrobiology patent

99.30 Press release: Expansion of a phase II clinical trial with Renal Cell Carcinoma

99.31 Press release: Lorus announces Virulizin Europe patent

99.32 Press release: Lorus announces the start of Leukemia clinical trial with GTI-2040 with NCI

99.33 Press release: Lorus allowed Canadian U-Sense patent

99.34 Press release; Lorus announces the starts of breast cancer study with GTI-2040 with NCI

99.35 Press release: Lorus announces a patent allowance for its subsidiary Nuchem

99.36 Press release: Lorus announces global expansion of Virulizin phase III trial

99.37 Press release: Lorus publishes results on Genetherapy

99.38 Press release: Lorus to present at BioContact 2003

99.39 Press release: Lorus to present results of GTI-2040 at AACR meeting

99.40 Press release: Lorus Supports PanCan awareness month

99.41 Press release: Lorus presents at Bio-Europe 2003 in Germany

99.42 Press release: Lorus announces Q1 04 results

99.43 Press release: Lorus participates in 39th ASCO meeting

.
.
.

<Table>
<Caption>

<S> | <C> | <C>
CONTACTS:
LORUS THERAPEUTICS INC. | CANADIAN MEDIA CONTACT: | US MEDIA CONTACT:

Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

Nancy Tamosaitis
Mansfield Communications Inc
Tel: (212) 370-5045
E-mail: nancyt@mcipr.com
</Table>

LORUS APPOINTS DR. ROBERT L. CAPIZZI TO BOARD OF DIRECTORS

- -NEW DIRECTOR BRINGS EXTENSIVE CLINICAL DRUG DEVELOPMENT EXPERIENCE TO COMPANY-

TORONTO, JANUARY 14, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced the appointment of Robert L. Capizzi, M.D. as a director of the company. Currently, Dr. Capizzi is president of Capizzi Clinical Resources Inc., a company that specializes in pharmaceutical drug development and regulatory affairs.

From 1996 to 2001, Dr. Capizzi served as professor of medicine and pharmacology, and as the Magee professor of medicine and chairman of the department of medicine at the Thomas Jefferson University in Philadelphia, PA. In addition, from 1991 to 1996, he was executive vice president, World Wide Research and Development for U.S. Bioscience Inc.

Dr. Capizzi has served on and chaired various boards of the U.S. National Institutes of Health, the American Cancer Society, national and international professional societies, and scientific advisory boards of multinational pharmaceutical companies. He has also lectured extensively and is the author and/or co-author of several hundred publications and presentations of original research and review articles in journals, periodicals and textbooks.

"Dr. Capizzi's exceptionally strong clinical drug development background in cancer, and valuable biopharmaceutical industry experience will be asset to the Lorus Board," said Mr. Strachan, chair of the board of directors, Lorus. "Dr. Capizzi's considerable experience in these areas are integral as Lorus develops its preclinical drug program and aggressively advances three of its anticancer drugs through clinical trials towards commercialization."

- 30 -

About Lorus
Lorus Therapeutics Inc. is a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer. With products in all stages of evaluation, from pre-clinical through Phase III trials, and a product approved in Mexico for malignant melanoma, Lorus is a leader in the development of therapeutics that seek to manage cancer with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

.
.
.

<Table>
<Caption>

<S> | <C> | <C>
CONTACTS:
LORUS THERAPEUTICS INC. | CANADIAN MEDIA CONTACT: | US MEDIA CONTACT:

Corporate Communications
Bruce Rowlands
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com

Hugh Mansfield
Mansfield Communications I
Tel: (416) 599-0024
Email: hugh@mcipr.com

Nancy Tamosaitis
Mansfield Communications Inc
Tel: (212) 370-5045
E-mail: nancyt@mcipr.com

</Table>

LORUS ANNOUNCES SEVERAL STAFF CHANGES

TORONTO, JANUARY 15, 2003 - Lorus Therapeutics Inc. today announced the retention of Mr. Bruce Rowlands as senior advisor, with special responsibilities in investor relations.

Mr. Rowlands brings a wealth of industry experience in the areas of corporate finance, institutional equity sales and investor communications to the Lorus team. Most recently, he served as vice president and director at Dominick & Dominick Securities Canada, an affiliate of Dominick & Dominick LLC in New York City.

During the past six years, Mr. Rowlands has participated in financings involving more than C$250 million for emerging North American companies including biotechnology companies. Since 1997, he has been involved in all of Lorus' financing transactions totaling over C$60 million.

"Mr. Rowlands' in-depth knowledge of both the biotechnology sector and the investment community in North America is important to Lorus as the company advances its preclinical and clinical drug development programs and executes its business plans," said Dr. Jim A. Wright, CEO, Lorus.

(more)

In other news, the company announced the departure of Mr. James Parsons as its chief financial officer effective January 10, 2003. Lorus thanks Mr. Parsons for his contributions to the company and wishes him well in his endeavors.

Ms. Ping Wei has been promoted from assistant controller to comptroller and has assumed responsibility for the accounting duties of the company. Ms. Wei holds chartered accountant, certified public accountant (Illinois) and certified general accountant designations and a Bachelor of Accounting degree. Prior to joining Lorus in 2001 she was employed as a senior staff accountant at Deloitte and Touche in Toronto.

Dr. Wright added, "Ms. Wei has demonstrated exceptional proficiency in her work, and I am very pleased to have both her and Mr. Rowlands on board and look forward to their contributions."

About Lorus
Lorus Therapeutics Inc. is a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer. With products in all stages of evaluation, from pre-clinical through Phase III trials, and a product approved in Mexico for malignant melanoma, Lorus is a leader in the development of therapeutics that seek to manage cancer with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no

obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Communications Inc.
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com
jennifer@mcipr.com

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:

Jennifer Taylor
Mansfield

Tel: (212) 370-5045
E-mail:

</Table>

LORUS THERAPEUTICS DESCRIBES RESEARCH FINDINGS ON ANTISENSE ANTI-TUMOR ACTIVITY AT 19TH ANNUAL ONCOGENE MEETING

- Company broadens its antisense pipeline -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, JUNE 20, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that its preclinical findings on the anti-tumor activity of thioredoxin antisense molecules will be presented today at the 19th Annual Oncogene Meeting at Hood College, Frederick, Maryland.

Lorus' presentation titled, "Anti-Tumor Activity of Antisense Oligodeoxynucleotides Targeted Against Human Thioredoxin," describes the company's study results, which will also be published in the conference meeting book.

Thioredoxin, a molecule involved in cancer cell growth and in protection of cancer cells from damage and death, has been implicated in tumor formation, progression and metastasis (spread of tumor cells) by a variety of mechanisms. A number of tumors including lung, colon, cervical, gastric and hepatocellular carcinoma, squamous cell carcinoma, myeloma, non-Hodgkins lymphoma, mesothelioma, and acute lymphocytic leukemia, showed elevated levels of thioredoxin.

Expression levels of thioredoxin correlate with malignancy and with proliferative index (a measure of the rate of cancer cell growth) and disease prognosis. Furthermore, the over-expression of thioredoxin has been linked with resistance to chemotherapeutic agents. Reducing the level of thioredoxin using antisense drugs should interfere with multiple pathways that lead to cancer progression, and as a result, there is the potential to inhibit tumor growth and metastasis.

(more)

Lorus' studies using human tumor cells and mouse models bearing human tumors support this approach. A number of antisense molecules designed to target thioredoxin were shown to significantly inhibit the growth of a variety of human tumor cells in culture. Furthermore, these molecules inhibited the growth and spread of human tumor cells in experimental tumor and metastasis models in mice. Based on these studies, Lorus has chosen a lead compound that demonstrated high anti-tumor efficacy.

"Lorus currently has two antisense therapeutics in clinical trials, GTI-2040 and GTI-2501, and has devoted an active research program to the discovery and evaluation of additional tumor targets amenable to antisense therapy," said Dr. Jim Wright, chief executive officer, Lorus. "The identification of thioredoxin antisense compounds with very promising anti-tumor activity adds significant value to this drug discovery program."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage

clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:

Amy Banek
Mansfield Communications Inc
Tel: (212) 370-5045
E-mail: amy@mcipr.com

</Table>

LORUS THERAPEUTICS WORKS WITH THE U.S. NATIONAL CANCER INSTITUTE IN THE CLINICAL DEVELOPMENT OF GTI-2040

- Agreement is an important achievement in Canadian cancer drug development -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, FEBRUARY 11, 2003 - Lorus Therapeutics Inc. ('Lorus') today announced that the company and the U.S. National Cancer Institute (NCI) have approved clinical protocols to conduct a series of clinical trials to investigate the safety and efficacy of its lead antisense drug, GTI-2040 in breast cancer, colon cancer, non-small cell lung cancer, acute myeloid leukemia, prostate cancer, and in a range of solid tumors.

Lorus and the NCI signed a formal clinical trial agreement in which the NCI will financially sponsor the GTI-2040 clinical trials, while Lorus will provide the drug.

Lorus and the NCI collaborated to select six cancer indications from 29 proposals submitted by major U.S. and Canadian oncology centers. The initial six studies represent the first stage of a clinical development partnership between Lorus and the NCI.

The agreement is the result of a successful Phase I clinical trial program and promising preclinical data, which demonstrates the effectiveness of GTI-2040 when used alone or in combination with standard anticancer agents in the treatment of a wide variety of tumors.

(more)

"This partnership with the NCI is a significant achievement for Lorus and for Canadian cancer drug development," said Dr. Jim Wright, CEO, Lorus. "The substantial financial support and outstanding expertise from this collaboration will enable us to determine the effectiveness of GTI-2040 across a range of tumor types, thereby identifying the patient population that will most benefit from drug treatment, and also identifying the optimal commercial path for the development of GTI-2040."

Dr. Wright added: "We are impressed by the level of interest expressed by U.S. and Canadian oncologists to participate in this exciting drug development program. The calibre of the proposals received by the NCI attests to the oncology community's confidence in the potential of the antisense approach used by Lorus for developing drugs like GTI-2040 to treat patients with cancer."

In addition to the collaboration between Lorus and the NCI , GTI-2040 is currently being investigated in a Phase II clinical trial in combination with capecitabine for the treatment of renal cell carcinoma. On February 5, 2003, Lorus announced that this promising clinical study was expanded to include six major oncology centers in the U.S.A.

The NCI is an agency of the National Institutes of Health (NIH), one of eight agencies that compose the public Health Service (PHS) in the U.S. Department of Health and Human Services (DHHS). The NCI, established under the National Cancer Act of 1937, is the U.S. Federal Government's principal agency for cancer research and training.

About Lorus
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public

company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Inc
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

<C>

CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>

US MEDIA CONTACT:

Amy Banek
Mansfield Communications

Tel: (212) 370-5045
E-mail: amy@mcipr.com

</Table>

LORUS THERAPEUTICS ALLOWED MEXICAN PATENT TO PROTECT LEAD PRODUCT VIRULIZIN(R)

- PATENT PROTECTS VIRULIZIN(R) IN ITS FIRST COMMERCIAL MARKET PLACE -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, FEBRUARY 17, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that a patent was allowed by the Mexican Patent Office to protect the company's intellectual property involving its lead immunotherapy drug, Virulizin(R).

The patent titled, 'Immunomodulator Composition, Process for Preparation, Pharmaceutical Compositions that Contain it and Uses of Same,' protects both the composition and use of Virulizin(R) for the treatment of cancer.

"This recent patent allowance fortifies our intellectual property position in Mexico, where Virulizin(R) is approved for the treatment of malignant melanoma," said Dr. Jim Wright, CEO, Lorus. "The allowance is critically important to our strategic plan for maximizing the value of Virulizin(R) in its first commercial marketplace."

Lorus and Mayne Pharma have entered into an exclusive seven-year distribution agreement for Mexico. Under the terms of the agreement, Lorus receives royalties from the sales of Virulizin(R) and is responsible for manufacturing the drug. Mayne Pharma recently exercised its option for similar agreements for Brazil and Argentina.

(more)

Virulizin(R) has been shown to be a non-toxic immunotherapy that recruits natural killer cells, moncoytes and macrophages, to attack tumor cells. In pre-clinical and clinical studies, Virulizin(R) has proven to be a well tolerated and an effective drug capable of antitumor activity in a range of cancer types, such as malignant melanoma and pancreatic cancer.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications	Hugh Mansfield	Amy Banek
Grace Tse	Mansfield Communications Inc.	Mansfield Communications Inc
Tel: (416) 798-1200, ext.380	Tel: (416) 599-0024	Tel: (212) 370-5045
Email: ir@lorusthera.com	Email: hugh@mcipr.com	E-mail: amy@mcipr.com

</Table>

LORUS PRESENTS VIRULIZIN(R) RESULTS AT 20TH NATIONAL MEDICAL MEETING OF THE "INSTITUTO NACIONAL DE CANCEROLOGIA"

- COMPANY PRESENTS VIRULIZIN(R) TO LATIN AMERICAN ONCOLOGISTS -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, FEBRUARY 21, 2003 - Lorus Therapeutics Inc. ("Lorus") is pleased to announce that its lead immunotherapy drug, Virulizin(R), will be featured today at a symposium at the 20th National Medical Meeting of the "Instituto Nacional de Cancerologia" (INCan) in Mexico City. The conference is attended by leading scientists and oncologists from Latin America and around the world.

Lorus senior management, scientific advisors and clinical investigators will present on Lorus' extensive discovery and clinical programs related to Virulizin(R). Ms. Suzanne Cadden, vice president of clinical and regulatory affairs will chair a symposium where Dr. J. G. de la Garza Salazar, director general of the INCan; Dr. M. Thirlwell of McGill University; and Dr. D. Braun of the Ohio Cancer Center will present their clinical and research experience pertaining to Virulizin(R) in the treatment of malignant melanoma to a select group of leading oncologists.

Also at the conference, Dr. A. H. Young, senior vice president and chief technology officer at Lorus will give a scientific presentation, entitled 'Virulizin(R), a novel immunotherapeutic agent, inhibits human tumor growth by activation of macrophages and NK cells.'

(more)

Virulizin(R) has been shown to be a non-toxic immunotherapy that recruits natural killer cells, moncoytes and macrophages, to attack tumor cells. In pre-clinical and clinical studies, Virulizin(R) has proven to be well-tolerated and an effective drug capable of antitumor activity in a range of cancer types, such as malignant melanoma and pancreatic cancer.

Virulizin(R) for the treatment of malignant melanoma is approved in Mexico and is commercially available in Mexico through Lorus' marketing partner Mayne Pharma. Commercial orders originally anticipated in 2002 were taken in early 2003 following routine regulatory and quality assurance testing by Mexican authorities.

"Today's presentations of Virulizin(R) at INCan are important to the ongoing commercialization process of the drug in Mexico," said Dr. Jim Wright, CEO, Lorus. "The INCan meeting is one of Latin America's most significant educational events for the oncology community. We, along with Mayne Pharma, are delighted to have the opportunity to present our scientific and clinical results to this respected and influential group of oncologists."

In other related news, Virulizin(R)is also in a multi-centre Phase III clinical trial in North America for the treatment of pancreatic cancer.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public

company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications Grace Tse Inc. Tel: (416) 798-1200, ext.380 Email: ir@lorusthera.com	Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	Jennifer Taylor Mansfield Communications Tel: (212) 370-5045 E-mail: jennifer@mcipr.com

</Table>

THE UNITED STATES FOOD AND DRUG ADMINISTRATION GRANTS ORPHAN DRUG STATUS TO LORUS THERAPEUTICS' GTI-2040 IN KIDNEY CANCER

- U.S. FDA designation enhances drug development program -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, MARCH 24, 2003 - Lorus Therapeutics Inc. ('Lorus') today announced that the U.S. Food and Drug Administration (FDA) has awarded orphan drug status to GTI-2040, the company's lead anticancer agent for the treatment of advanced kidney (renal cell) cancer. GTI-2040 is currently in a Phase II clinical trial program in major North American cancer centers for the treatment of renal cell cancer.

For Lorus, receiving orphan drug status for GTI-2040 in the treatment of renal cell cancer means that the FDA will help to facilitate the drug's development process by providing financial incentives and granting seven years of market exclusivity in the U.S. (independent of patent protection) upon approval of the drug in the U.S.

Specifically, orphan drug status results in costs savings from a number of tax benefits, the opportunity to obtain additional financial support from the U.S. government for clinical study costs, and exemption from certain fees at the time of submission of GTI-2040 to the FDA for marketing approval. Orphan drug designation typically means that FDA marketing review times are expedited in comparison to other drugs since orphan drug status denotes serious or life-threatening diseases that afflict less than 200,000 patients annually in the U.S.

(more)

"The commitment of the U.S FDA is important to companies like Lorus, whose business strategy includes advancing new treatments in clinical development for debilitating diseases like kidney cancer," said Dr. Jim Wright, CEO, Lorus. "This support helps Lorus optimize the commercial potential of GTI-2040 in this cancer indication, and enhances our continuing track-record of success as an innovative cancer research and drug development company."

In partnership with the United States National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) under a clinical trials agreement, Lorus and CTEP are expanding the Phase II clinical development of GTI-2040 to include additional clinical trials for the treatment of other cancer types.

Renal cell carcinoma is the most common type of kidney cancer with more than 34,000 cases diagnosed annually in North America. The majority of patients are over the age of 40. More than 10,000 patients die annually from this disease in the U.S., and 100,000 worldwide. The age-adjusted world incidence in renal cell carcinoma has been increasing steadily at an annual rate of approximately two per cent. In advanced metastatic renal cell carcinoma patients, the five-year survival rate is approximately 10 per cent. Current treatments include interferon, interluekin-2 (IL-2), and Proleukin, the only approved drug for the treatment of renal cell carcinoma. The use of these agents is limited due to serious toxicities in many patients. There is a clear need for drugs with lower toxicities to treat patients with this difficult disease. In this regard, GTI-2040 has shown a high safety profile in preclinical and clinical studies.

About Lorus
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic

pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

CONTACT

LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

CANADIAN MEDIA:
MANSFIELD COMMUNICATIONS INC.
Hugh Mansfield
Tel: (416) 599-0024
Email: hmansfield@mcipr.com

TSE: LOR
OTC BB: LORFF

LORUS THERAPEUTICS REPORTS SECOND QUARTER RESULTS

TORONTO, CANADA - JANUARY 17, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced second quarter 2003 financial results for the quarter ended November 30, 2002. All figures, unless otherwise specified, are in Canadian dollars.

SEPTEMBER 1, 2002 TO DATE HIGHLIGHTS

- A steering group has been formed with representatives from the U.S. National Cancer Institute (NCI) to determine the cancer indications and protocols of multiple Phase II clinical trials for GTI-2040. The trials will be conducted by the NCI in conjunction with Lorus.

- Allowed patent protection by the United States Patent and Trademark Office (USPTO) to protect the company's lead anticancer drug Virulizin(R) as it relates to immunodulating compositions, pharmaceutical agents containing these compositions, and the use of the compositions and agents for treatment purposes.

- Received patent on NC381, the lead anticancer drug of a subsidiary of Lorus, NuChem Pharmaceuticals Inc. from USPTO. The patent protects NC381 as an effective therapeutic agent for the treatment of lung, pancreatic and skin cancers, and as an inhibitor of prostate tumor growth.

- Mayne Pharma exercised its option to secure distribution rights for Virulizin(R) in Argentina for the treatment of malignant melanoma. This increases the scope of Lorus' relationship with Mayne Pharma and the potential of revenues from the emerging markets in South America.

- Renewed emergency drug program to supply Virulizin(R) for the treatment of advanced pancreatic cancer around the world which not only provides a valuable service to cancer patients not otherwise eligible for ongoing clinical trials but also augments the Virulizin(R) database with additional safety information.

- Appointed Mr. Graham Strachan as the chair of the board of directors and Mr. J. Kevin Buchi as a director of the board.

"In this quarter, we continued to build shareholder value at Lorus by obtaining patent protection of our inventions and through the advancement of our clinical programs," said Dr. Jim A. Wright, chief executive officer, Lorus. "The agreement to carry out multiple clinical trials with GTI-2040 in partnership with the U.S. NCI further validates our lead antisense drug and provides financial support to assess the efficacy of this novel drug in a variety of cancer indications.

" For the second quarter ended November 30, 2002, Lorus incurred a loss of $3,969,000 ($0.03 per share) compared to a loss of $3,683,000 ($0.03 per share) for the second quarter last year. On a year-to-date basis, the loss was $8,045,000 ($0.06) for the first six months of fiscal 2003 compared to $6,739,000 ($0.05) for the comparable period last year. The increase in net loss relates primarily to greater costs for the Virulizin(R) Phase III clinical trial and the antisense clinical development programs as planned and lower interest income, partially offset by lower administrative costs from cost conservation efforts and lower goodwill amortization due to a recent accounting pronouncement effective June 1, 2002. On a comparable basis, the loss for the three months and six months ended November 30, 2001 would have been $3,321,000 ($0.02 per share) and $6,012,000 ($0.04 per share) respectively after adjustment to remove amortization of goodwill in those periods.

Research and development expenses for the second quarter of fiscal 2003 increased to $3,323,000 compared to $2,093,000 for the same quarter last year. For the six months ended November 30, 2002 research and development expenses increased to $6,370,000 compared to $4,235,000 for the same period last year. Costs increased in fiscal 2003 due primarily to higher clinical trial costs for Virulizin(R) for the ongoing pivotal Phase III trial for the treatment of advanced pancreatic cancer. The antisense clinical program which includes the GTI-2040 Phase II trial in patients with renal cell carcinoma and the GTI-2501 Phase I trial in patients with solid tumors or lymphoma also contributed to the increase in the current periods.

General and administrative expenses for the second quarter of fiscal 2003 decreased to $796,000 compared to $1,583,000 for the same quarter last year. For the six months ended November 30, 2002 general and administrative expenses decreased to $2,100,000 compared to $2,645,000 for the same period last year. The decrease in both periods was due mainly to lower use of external advisory services. For the six months ended November 30, 2002 this decrease was partially offset by higher employee related costs that occurred in the first quarter.

Depreciation and amortization for the second quarter of fiscal 2003 decreased to $164,000 from $567,000 for the same quarter last year. For the six months ended November 30, 2002 depreciation and amortization expenses decreased to $259,000 from $1,022,000 during the same period last year. In both periods, the decrease was due mainly to the adoption of the new CICA accounting guideline for goodwill and other intangible assets whereby the Company ceased amortizing goodwill on June 1, 2002.

Interest income for the second quarter of fiscal 2003 decreased to $314,000 from $560,000 for the same quarter last year. For the six months ended November 30, 2002 interest income decreased to $684,000 from $1,163,000 for the same period last year. The decrease was due primarily to lower cash and short-term investments balances in fiscal 2003 compared to the comparable periods in fiscal 2002.

As at November 30, 2002, Lorus had cash and cash equivalents and short-term investments of $31.7 million compared to $37.8 million at May 31, 2002.

CONSOLIDATED STATEMENTS OF LOSS (UNAUDITED)
FOR THE QUARTERS ENDED NOVEMBER 30, 2002 AND 2001

<TABLE>
<CAPTION>

(Amounts in 000's except for per common share data) (Canadian Dollars)	THREE MONTHS ENDED NOV. 30, 2002	Three months ended Nov. 30, 2001	SIX MONTHS ENDED NOV. 30, 2002	Six months ended Nov. 30, 2001
<S>	<C>	<C>	<C>	<C>
EXPENSES				
Research and development	$ 3,323	$ 2,093	6,370	$ 4,235
General and administrative	796	1,583	2,100	2,645
Depreciation and amortization	164	567	259	1,022
Interest income	(314)	(560)	(684)	(1,163)
LOSS FOR THE PERIOD	3,969	3,683	8,045	6,739
Deficit, beginning of period	78,945	64,438	74,869	61,382
DEFICIT, END OF PERIOD	$ 82,914	$ 68,121	$ 82,914	$ 68,121
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.03	$ 0.03	$ 0.06	$ 0.05
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING USED IN THE CALCULATION OF BASIC AND DILUTED LOSS PER SHARE	144,422	143,166	144,419	142,805

</TABLE>

Media, members of the financial community and shareholders are invited to listen to Company's quarterly earnings conference call through the live audio webcast on the Company's website at www.lorusthera.com Friday, January 24, 2003 at 2:00 p.m. (EST). The conference call webcast will also be archived at

www.lorusthera.com.

A telephone replay of the conference call will also be available from approximately 4:00p.m. (EST) Friday, January 24, 2003 until 11:59p.m. Friday, January 31, 2003. To access the replay, call 1-877-289-8525 and enter reservation number 233848#.

About Lorus

Lorus Therapeutics Inc. is a biopharmaceutical company specialising in the research, development and commercialisation of pharmaceutical products and technologies for the management of cancer. With products entering all stages of evaluation, from pre-clinical through Phase III trials, Lorus is a leader in the development of therapeutics that complement the new cancer treatment paradigm that seeks to manage the disease with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: HTTP://WWW.LORUSTHERA.COM.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications Grace Tse Tel: (416) 798-1200, ext.380 Email: ir@lorusthera.com	Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	Jennifer Taylor Mansfield Communications Inc Tel: (212) 370-5045 E-mail: jennifer@mcipr.com

</Table>

LORUS TO ADVANCE ITS ANTICANCER DRUG, GTI-2501 INTO PHASE II CLINICAL TRIAL

- Drug to progress to Phase II clinical trial for the treatment of prostate cancer -

TSE: LOR
OTC BB: LORFF

TORONTO, MAY 21, 2003 - Lorus Therapeutics Inc. ('Lorus') today announced its intention to move its antisense, anticancer drug, GTI-2501 into a Phase II clinical trial for the treatment of advanced metastatic prostate cancer in the fall of 2003. Lorus has signed a Letter of Intent to conduct this clinical study with Dr. Laurence Klotz of the Sunnybrook and Women's College Health Sciences Center in Toronto, Canada.

Dr. Klotz is currently chief of the Division of Urology at Sunnybrook Hospital, chair of the Canadian Urology Research Consortium, and a founder of the Prostate Cancer Research Foundation of Canada.

GTI-2501 reduces the expression of the R1 component of ribonucleotide reductase to prevent tumor cell growth. Data from Phase I clinical studies nearing completion meet the safety and tolerability milestones required for advancement to a Phase II clinical trial. In preclinical investigations, GTI-2501 selectively and specifically inhibited tumor growth across a broad range of tumor types, including several models of prostate cancer. This included both hormone dependent prostate cancer, and prostate cancer that is resistant to hormone blocking drugs. GTI-2501 also significantly enhanced the anti-tumor effects of standard agents currently used for the treatment of prostate cancer.

(more)

"We are extremely pleased to be advancing GTI-2501 in clinical development in partnership with a leading Canadian oncology center," said Dr. Jim Wright, CEO of Lorus. "This clinical trial is consistent with our business strategy, which is to rapidly advance promising anticancer drugs in the clinic, and to progress several drugs through the drug development process to enhance the commercial opportunities of our strong product pipeline."

Prostate cancer is the most frequently diagnosed cancer in North American men and the second leading cause of cancer deaths. It is estimated that over 1 million North American men now alive over the age of 50 will die of prostate cancer unless new treatments are developed to control this devastating disease. As our population ages, the effect of prostate cancer is expected to increase. In comparison to other cancer types, prostate cancer has the greatest increase in both mortality and incidence with increasing age, and impacts significantly on health care systems. It is estimated that approximately $5 billion is spent on prostate cancer treatments each year in the United States and Canada.

In addition to GTI-2501 Lorus has two other anticancer drugs in clinical trials. GTI-2040 has recently received orphan drug status from the United States Food and Drug Administration (FDA) and is in a Phase II clinical trial in the United States for the treatment of renal cell carcinoma. Virulizin(R) is in a pivotol Phase III clinical trial in North America for the treatment of pancreatic cancer and was awarded orphan drug status and fast track status by the FDA. Virulizin(R) is also approved in Mexico for the treatment of malignant melanoma and is commercially available in Mexico through Mayne Pharma, Lorus' marketing partner.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage

clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Inc.
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:

Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
E-mail: jennifer@mcipr.com
</Table>

LORUS THERAPEUTICS INC. PUBLISHES RESULTS OF VIRULIZIN(R) ANTI-TUMOUR ACTIVITY IN PEER REVIEWED SCIENTIFIC JOURNAL

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, MARCH 27, 2003 - Scientists at Lorus Therapeutics Inc. ("Lorus") have published the results of experimental studies in mouse models bearing human tumors treated with Virulizin(R), the company's lead anti-cancer immunotherapeutic drug. The results appear in an article titled, "Anti-tumor activity of Virulizin(R), a novel biological response modifier (BRM), in a panel of human pancreatic cancer and melanoma xenografts," in Cancer Chemotherapy and Pharmacology, Volume 51, Issue 3, pages 247-255, 2003.

Virulizin(R) showed significant anti-tumor activity as a monotherapy and enhanced anti-tumor effects when used in combination with standard chemotherapy agents against a panel of human pancreatic tumors and melanoma.

Data describing the pharmacological activity of Virulizin(R) as reported in the publication, will be an important addition to the preclinical component of regulatory dossiers required to obtain marketing approval for this drug.

"These results demonstrate the very promising anti-cancer properties of Virulizin(R) and are consistent with the findings of Phase I and Phase II clinical trials performed with Virulizin(R)," said Dr. Jim Wright, chief executive officer. "Publishing in international peer reviewed journals reflects Lorus' strong commitment to research and to maintaining high scientific standards in the company's drug development process."

(more)

Virulizin(R) was awarded orphan drug status and fast-track status from the United States Food and Drug Administration in clinical studies for the treatment of pancreatic cancer. The drug is approved in Mexico for the treatment of melanoma and is commercially available in Mexico through Lorus' marketing partner Mayne Pharma. Virulizin (R) is currently in a Phase III clinical trial in North America for the treatment of pancreatic cancer in combination with gemcitabine.

About Lorus
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Inc.
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:

Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
E-mail: jennifer@mcipr.com
</Table>

LORUS THERAPEUTICS ANNOUNCES UNITED STATES PATENT ALLOWANCE TO PROTECT VIRULIZIN(R), THE COMPANY'S MOST CLINICALLY ADVANCED ANTI-CANCER DRUG

- Third U.S. patent allowance for Virulizin(R) -

TSE: LOR
OTC BB: LORFF

TORONTO, APRIL 2, 2003 - Lorus Therapeutics Inc. ("Lorus") reported today that it has received notice from the United States Patent and Trademark Office of the allowance of a patent, which protects the company's intellectual property for its lead immunotherapeutic anti-cancer product, Virulizin(R). This drug is currently in a Phase III clinical trial in the United States for the treatment of pancreatic cancer and is commercially available in Mexico for the treatment of malignant melanoma.

The patent titled, "Immunomodulating compositions for treatment of immune system disorders," is the third U.S. patent allowance for Virulizin(R). Previous patents protect the only known production process for Virulizin(R) and the composition produced according to this process and methods for stimulating a patient's immune system with Virulizin(R) for treatment purposes. The most recent patent significantly broadens protection to include methods for treatment of a variety of different cancers.

"As investigations at Lorus continue to expand the potential uses of Virulizin(R) for treatment of malignant diseases, it is our strategy to protect these novel findings and broaden the patent portfolio for this anti-cancer agent," said Dr. Jim Wright, chief executive officer, Lorus. "This strategy enables Lorus to maximize the commercial potential of Virulizin(R) in marketplaces like the United States, which is the largest market for anti-cancer drugs in the world."

(more)

The United States Food and Drug Administration has awarded Virulizin(R) orphan drug status and fast track status for the treatment of pancreatic cancer. The drug is currently in a Phase III clinical trial in North America for the treatment of pancreatic cancer, and has been approved in Mexico for the treatment of malignant melanoma, where it is commercially available through Mayne Pharma, Lorus' marketing partner in Latin America.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings,

annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC. Corporate Communications Grace Tse Inc. Tel: (416) 798-1200, ext.380 Email:ir@lorusthera.com	CANADIAN MEDIA CONTACT: Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	US MEDIA CONTACT: Jennifer Taylor Mansfield Communications Tel: (212) 370-5045 E-mail: jennifer@mcipr.com

</Table>

LORUS THERAPEUTICS ALLOWED CANADIAN PATENT TO PROTECT INVENTION
OF NOVEL ANTISENSE ANTIMICROBIAL DRUGS

- Patent protects antimicrobial drug discovery program -

TSX: LOR
OTC BB: LORFF

TORONTO, APRIL 9, 2003 - Lorus Therapeutics Inc. ('Lorus') announced today that the Canadian Patent Office has allowed a patent, which protects a new component of the company's antisense drug development program that shows promising antimicrobial activity.

The patent titled, 'Antisense Oligonucleotide Sequences As Inhibitors of Microorganisms,' protects Lorus' technology on the design and use of unique antisense, antimicrobial agents that target specific microbial gene sequences.

The patent covers two gene targets, SecA and Ribonucleotide reductase (RNR), which are necessary for growth and viability of microorganisms. SecA is a central component of a process required for secretion of microbial proteins, which is an essential event in the life cycle of pathogenic organisms. RNR is a central enzyme in the formation of components required for DNA synthesis and repair in bacteria, fungi and viruses. The essential functions of these gene products make them ideal targets for drug development.

"The expanding health problem of the emergence of multi-drug resistant bacteria and of new strains of viruses underscores the need for the development of new antimicrobial therapeutics," said Dr. Jim A. Wright, chief executive officer, Lorus. "The company believes that antisense-mediated inhibition of the expression of SecA and RNR can lead to the development of novel antimicrobial agents for combating this emerging health problem."

(more)

Dr. Wright added: "This patent represents an expansion of the antisense platform to development of novel antimicobial drugs and further strengthens the company's intellectual property portfolio, covering its antisense technology."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

CONTACT

LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

CANADIAN MEDIA:
MANSFIELD COMMUNICATIONS INC.
Hugh Mansfield
Tel: (416) 599-0024
Email: hmansfield@mcipr.com

TSE: LOR
OTC BB: LORFF

LORUS THERAPEUTICS REPORTS THIRD QUARTER RESULTS

TORONTO, CANADA - APRIL 11, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced third quarter financial results for the quarter ended February 28, 2003. All figures, unless otherwise specified, are in Canadian dollars.

DECEMBER 1, 2002 TO DATE HIGHLIGHTS

- A milestone was achieved in the quarter, as the Company recorded its first ever revenue in the company's history from the sale of Virulizin(R) in Mexico.
- The Company expanded the ongoing phase II clinical trial of GTI-2040 in renal cell carcinoma from one site to six major oncology centers in the U.S.
- The U.S. National Cancer Institution (NCI) approved six protocols in a multiple phase II clinical trial program with GTI-2040 including breast cancer, colon cancer, non-small cell lung cancer, acute myeloid leukemia, prostate cancer, and a range of solid tumors.
- GTI-2040 was awarded Orphan Drug Status by the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma. This status allows the FDA to help facilitate the drug's development process by providing financial incentives and granting seven years of market exclusivity in the U.S. independent of patent protection upon approval of the drug in the U.S.
- The United States Patent and Trademark Office (USPTO) allowed Lorus another patent to protect the company's lead anticancer drug Virulizin(R) as it relates to immunomodulating compositions for the treatment of immune system disorders.
- The Mexican Patent Office allowed Lorus a patent to protect the immunomodulator composition, process for preparation and use of Virulizin(R) for the treatment of cancer. The allowance is critically important to Lorus' strategic plan for maximizing the value of Virulizin(R) in its first commercial marketplace.
- Appointed Dr. Robert Capizzi who is a seasoned oncologist to the board of directors and retained the services of Mr. Bruce Rowlands, who is an experienced professional with in-depth knowledge of public market and investor relations, as its Senior Advisor with responsibilities in the area of Investor Relations.

"We are pressing full speed ahead to enhance shareholder value in this quarter. We expanded our clinical trials, continuously enhanced our patent portfolios and strengthened the board and management team," said Dr. Jim A. Wright, chief executive officer, Lorus. "Support from the NCI through the sponsorship of

six additional GTI-2040 clinical trials provides scientific and clinical validation of our antisense drug development program in the U.S., the largest cancer drug market in the world."

Net loss for the third quarter ended February 28, 2003 totaled $3,802,000 ($0.026 per share) compared to a loss of $3,028,000 ($0.021 per share) for the same quarter last year. The loss was $11,847,000 ($0.082 per share) for the first nine months of fiscal 2003 compared to $9,767,000 ($0.068 per share) for the comparable period last year. The increase in net loss relates primarily to higher level of activities with the Virulizin(R) Phase III clinical trial and expanded GTI-2040 phase II trials and lower interest income, partially offset by lower administrative costs from cost conservation efforts and the ceasing of amortization of goodwill in accordance with the adoption of a new accounting pronouncement effective June 1, 2002. On a comparable basis, the loss for the three months and nine months ended February 28, 2002 would have been $2,664,000 ($0.019 per share) and $8,676,000 ($0.061 per share) respectively after adjustment to remove the amortization of goodwill.

Research and development expenses for the third quarter of fiscal 2003 increased to $2,876,000 compared to $1,872,000 for the same quarter last year. For the nine months ended February 28, 2003, research and development expenses increased to $9,246,000 compared to $6,107,000 for the same period last year. Cost

increases in fiscal 2003 can be attributed primarily to higher clinical trial costs for the ongoing pivotal Phase III trial of Virulizin(R) for the treatment of advanced pancreatic cancer and an expanded GTI-2040 phase II trial in patients with renal cell carcinoma.

General and administrative expenses for the third quarter of fiscal 2003 decreased to $960,000 compared to $1,209,000 for the same quarter last year. For the nine months ended February 28, 2003, general and administrative expenses decreased to $3,060,000 compared to $3,854,000 for the same period last year. The decrease in both periods was due mainly to lower use of external advisory services, and ongoing cost containment.

Depreciation and amortization for the third quarter of fiscal 2003 decreased to $224,000 from $458,000 for the same quarter last year. For the nine months ended February 28, 2003, depreciation and amortization expenses decreased to $483,000 from $1,480,000 during the same period last year. In both periods, the decrease was due mainly to the adoption of the new CICA accounting pronouncement for goodwill and other intangible assets whereby the Company ceased amortizing goodwill on June 1, 2002.

Interest income for the third quarter of fiscal 2003 decreased to $258,000 from $511,000 for the same quarter last year. For the nine months ended February 28, 2003, interest income decreased to $942,000 from $1,674,000 for the same period last year. These decreases can be attributed primarily to lower cash and short-term investments balances in fiscal 2003.

At February 28, 2003 Lorus had cash and cash equivalents and short-term investments totaling $27.7 million compared to $37.8 million at May 31, 2002. Working capital was $24.3 million at February 28, 2003 compared to $35.6 million at May 31, 2002.

CONSOLIDATED STATEMENTS OF LOSS (UNAUDITED)
FOR THE QUARTERS ENDED FEBRUARY 28, 2003 AND 2002

<TABLE>
<CAPTION>

(Amounts in 000's except for per common share data) (Canadian Dollars)	THREE MONTHS ENDED FEB. 28, 2003	Three months ended Feb. 28, 2002	NINE MONTHS ENDED FEB. 28, 2003	Nine months ended Feb. 28, 2002
<S>	<C>	<C>	<C>	<C>
REVENUES				
Product sales	$ 27	$ --	$ 27	$ --
OPERATING EXPENSES				
Cost of sales	27	--	27	--
Research and development	2,876	1,872	9,246	6,107
General and administrative	960	1,209	3,060	3,854
Depreciation and amortization	224	458	483	1,480
OPERATING LOSS	4,060	3,539	12,789	11,441
INTEREST INCOME	(258)	(511)	(942)	(1,674)
LOSS FOR THE PERIOD	3,802	3,028	11,847	9,767
Deficit, beginning of period	82,914	68,121	74,869	61,382
DEFICIT, END OF PERIOD	$ 86,716	$ 71,149	$ 86,716	$ 71,149
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.026	$ 0.021	$ 0.082	$ 0.068
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING USED IN THE CALCULATION OF BASIC AND DILUTED LOSS PER SHARE	144,433	143,898	144,424	143,170

	---------	---------	---------

</TABLE>

Media, members of the financial community and shareholders are invited to listen to Company's quarterly earnings conference call through the live audio webcast on the Company's website at www.lorusthera.com Tuesday, April 15, 2003 at 2:30 p.m. (EST). The conference call webcast will also be archived at www.lorusthera.com.

A telephone replay of the conference call will also be available from approximately 4:00p.m. (EST) Tuesday, April 15, 2003 until 11:59p.m. Tuesday, April 29, 2003. To access the replay, call 1-877-289-8525 and enter reservation number 247205#.

About Lorus
Lorus Therapeutics Inc. is a biopharmaceutical company specialising in the research, development and commercialisation of pharmaceutical products and technologies for the management of cancer. With products entering all stages of evaluation, from pre-clinical through Phase III trials, Lorus is a leader in the development of therapeutics that complement the new cancer treatment paradigm that seeks to manage the disease with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products

and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: HTTP://WWW.LORUSTHERA.COM.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Communications Inc.
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com
jennifer@mcipr.com
</Table>

<C>

CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>

US MEDIA CONTACT:

Jennifer Taylor
Mansfield

Tel: (212) 370-5045
E-mail:

LORUS THERAPEUTICS INC. ANNOUNCES PHASE III CLINICAL TRIAL PROGRESS WITH ITS LEAD IMMUNOTHERAPEUTIC DRUG, VIRULIZIN(R)

- Trial expanded to approximately 50 sites in North and Latin America -

TSE: LOR
OTC BB: LORFF

TORONTO, APRIL 16, 2003 - Lorus Therapeutics Inc. ('Lorus') today announced that its lead immunotherapeutic drug Virulizin(R), for the treatment of advanced pancreatic cancer currently in a pivotal Phase III clinical trial, is being expanded to include approximately 50 clinical trial sites in North America and Latin America.

In addition to approximately 40 clinical sites and several new major cancer centers throughout the United States, the company has expanded the trial to 10 major oncology centers in Canada and Mexico. Participating Canadian centers include McGill University in Montreal and the Cross Cancer Center in Edmonton Alberta. In Mexico it will include the National Cancer Institute of Mexico and the National Medical Center in Mexico City, which are two of Latin America's leading oncology centers.

The Virulizin(R) Phase III clinical trial examines the drug in a first-line treatment setting in combination with gemcitabine, the only agent currently approved for the treatment of advanced pancreatic cancer. The same clinical trial also examines Virulizin(R) in combination with 5-flurouracil as a second line treatment option for patients that become resistant or intolerant to gemcitabine treatment.

"We are very pleased to be a part of the Virulizin(R) Phase III clinical trial of first-line treatment of advanced pancreatic cancer," said Dr. Richard Just, Scripps Cancer Center, San Diego, California. "Virulizin(R) shows promise as a well-tolerated immunotherapeutic drug for a devastating disease that is characterized by very few new treatment options."

(more)

Ongoing clinical study sites for Virulizin(R) are located throughout the U.S., such as New York, California, Florida, Michigan, Louisiana, and Ohio. Details of the Phase III clinical study design and contact information have been posted on major oncology and pancreatic clinical trial web sites to facilitate awareness of the clinical trial in the health-care community.

"We are very impressed with the enthusiasm of our clinical investigators and study staff in our Phase III clinical program for Virulizin(R). Expansion of this trial to important oncology centers in Canada, Mexico, and the addition of new US sites is not only important for our clinical trial milestones, but is also central to our longer term global business strategy to have a strong presence in international markets, and the international oncology community," said Dr. Jim Wright, CEO, Lorus.

The US Food and Drug Administration awarded Virulizin(R) orphan drug status and fast track status for the treatment of pancreatic cancer. The drug has been approved in Mexico for the treatment of malignant melanoma, where it is commercially available through Mayne Pharma, Lorus' marketing partner in Latin America.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage

clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Inc.
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com
jennifer@mcipr.com
</Table>

<C>

CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>

US MEDIA CONTACT:

Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
E-mail:

LORUS THERAPEUTICS' SCIENTIFIC PUBLICATION EXPANDS THE POTENTIAL ANTICANCER APPLICATIONS OF VIRULIZIN(R)

- Studies published in peer reviewed scientific journal -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, APRIL 23, 2003 - Lorus Therapeutics Inc. ('Lorus') has published the results of experimental studies demonstrating the anti-tumor activity of Virulizin as a monotherapy and in combination with standard chemotherapy drugs. These studies, carried out in mouse models bearing human tumors, are unique as they expand the potential application of Virulizin(R) to include breast, ovarian and prostate cancers.

The findings of the study are published in an April issue of Anti-Cancer Drugs (volume 14, issue 4, pages 289 to 294, 2003) in an article entitled, "Preclinical efficacy of Virulizin(R) in human breast, ovarian and prostate tumor models." These results complement previously published data that demonstrated the effectiveness of Virulizin(R) as an anti-tumor agent in human pancreatic cancer and melanoma mouse models in Cancer Chemotherapy and Pharmacology (volume 51,issue 3, pages 247-255, 2003).

The published results will be included in the preclinical portion of regulatory submissions needed to obtain marketing approval for Virulizin(R).

(more)

"These recently published preclinical studies provide information for determining further clinical development and expansion of the indications for Virulizin(R), our lead anticancer immunotherapy drug. Reporting findings in peer reviewed scientific journals further validate the results from our research program, adds to our regulatory dossier and enhances our drug development activities," said Dr. Jim Wright, chief executive officer, Lorus.

Virulizin (R) is currently in a Phase III clinical trial in North America for the treatment of pancreatic cancer, and was awarded orphan drug status and fast-track status from the United States Food and Drug Administration in clinical studies for the treatment of pancreatic cancer. The drug is approved in Mexico for the treatment of melanoma and is commercially available in Mexico through Lorus' marketing partner.

About Lorus
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product

development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Inc
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com
jennifer@mcipr.com
</Table>

<C>

CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>

US MEDIA CONTACT:

Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
E-mail:

LORUS THERAPEUTICS INC. PUBLISHES RESULTS OF GTI-2040 ANTI-TUMOUR ACTIVITY AGAINST A BROAD RANGE OF CANCERS

- Cancer Research publication of scientific findings -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, JUNE 6, 2003 - Scientists at Lorus Therapeutics Inc. ("Lorus") have published the results of experimental studies in mouse models bearing human tumors treated with GTI-2040, the company's lead antisense compound. The results appear in an article titled, "GTI-2040, An Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Anti-tumor Activity against A Variety of Tumors," in the June issue of Cancer Research (Volume 63, issue 11, pages 2802-2811, 2003).

The publication summarizes results from studies that demonstrated the highly specific anti-tumor activity of GTI-2040 when used to treat twelve different human tumors including renal, breast and colon cancers. This latest article adds to a growing list of publications in peer reviewed scientific journals by Lorus, and marks the first major publication of detailed scientific findings for Lorus' antisense platform.

"We are pleased to have had the results of our GTI-2040 studies published in a high impact scientific journal," said Dr. Jim Wright, chief executive officer, Lorus. "The published results support our clinical development program for GTI-2040 and its potential as an anti-cancer therapy to treat a variety of different cancer indications."

(more)

GTI-2040 is Lorus' most advanced antisense drug in the clinic, and is currently in a Phase II clinical trial in the United States for the treatment of renal cancer in combination with capecitabine. In collaboration with the United States National Cancer Institute, Lorus intends to expand its Phase II clinical development program for GTI-2040 to include additional clinical trials to treat a variety of other human cancer indications.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of

corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications Grace Tse Communications Inc. Tel: (416) 798-1200, ext.380 Email:ir@lorusthera.com jennifer@mcipr.com	Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	Jennifer Taylor Mansfield Tel: (212) 370-5045 E-mail:

</Table>

LORUS THERAPEUTICS ANNOUNCES VIRULIZIN(R) PRESENTATION AT THE 5TH ANNUAL LUSTGARTEN FOUNDATION SCIENTIFIC CONFERENCE

- Co-sponsored by Dana-Farber Cancer Institute and Harvard Medical School -

TSE: LOR
OTC BB: LORFF

TORONTO, JUNE 17, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that data on its lead immunotherapeutic anticancer drug Virulizin(R)'s mode of action was accepted for a presentation at the 5th Annual Lustgarten Foundation Scientific Conference being held in Boston, Massachusetts on June 16 and 17, 2003. The poster presentation of preclinical and clinical findings is entitled, 'Stimulation of Natural Killer Cell function in Pancreatic Cancer with Virulizin(R), an Immunotheraepeutic Agent.'

The conference targets researchers and community based oncologists worldwide. The Lustgarten Foundation for Pancreatic Cancer Research is the largest private foundation dedicated exclusively to supporting pancreatic cancer research.

"We are pleased to be a part of the Lustgarten Foundation's 5th Annual Scientific Conference. This is a valuable clinical and scientific event bringing together clinicians and researchers in an important cause for the improvement of pancreatic cancer care," said Dr. Jim Wright, chief executive officer, Lorus. "The Lustgarten Foundation provides scientific and patient care leadership for a devastating disease where few treatment options exist for patients."

(more)

Virulizin(R) is currently in a pivotal North American Phase III clinical trial for the first-line treatment of advanced pancreatic cancer in combination with gemcitabine. Preclinical and earlier clinical studies using Virulizin(R) as a treatment supported a mechanism of action through enhanced immune cell activity, including Natural Killer (NK) cell function, across a number of cancer types including pancreatic cancer.

Recent preclinical studies demonstrate that NK cells infiltrate tumors following Virulizin(R) treatment. It is believed that low NK cell activity may be a risk factor for cancer or cancer spread, and a negative prognostic indicator in pancreatic cancer. Therefore, a drug that stimulates NK cell activity has the potential to be a valuable anticancer tool. In addition to primary and secondary endpoints, such as survival and clinical benefit, the current Phase III clinical trial will also examine NK cell function and other immune parameters as potential biologic markers of therapeutic response.

The Lustgarten Foundation concentrates its efforts on helping the scientific community work towards finding a cure for pancreatic cancer. The Foundation has awarded $9 million in support of promising pancreatic research and has sponsored four international scientific meetings at leading institutions. The Foundation also provides patient information through the dissemination of handbooks and a comprehensive Web site, and promotes pubic awareness of this devastating disease through a public service announcement campaign featuring former President Jimmy Carter, who also serves as honorary chairman of the Foundation's corporate advisory board.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be

used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications Grace Tse Communications Inc. Tel: (416) 798-1200, ext.380 Email:ir@lorusthera.com jennifer@mcipr.com	Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	Jennifer Taylor Mansfield Tel: (212)370-5045 E-mail:

</Table>

TSX: LOR
OTCBB: LORFF

LORUS THERAPEUTICS REPORTS YEAR-END RESULTS

-A YEAR OF PROGRESS AND SHAREHOLDER VALUE ENHANCEMENT -

TORONTO, CANADA - JULY 18, 2003 - Lorus Therapeutics Inc. ("Lorus") today reported financial results for the year ended May 31, 2003. Unless specified otherwise, all amounts are in Canadian dollars.

YEAR 2003 AND SUBSEQUENT HIGHLIGHTS

- Raised aggregate proceeds of $32.8 million by way of a public offering of units at a price of $1.25 per unit with each unit consisting of one common share and one-half of one purchase warrant.
- Expanded the pivotal phase III trial of its lead immunotherapeutic drug Virulizin(R) for the treatment of advanced pancreatic cancer to over 50 North American and Latin American sites
- Recorded it's first commercial revenue from sales of Virulizin(R) in Mexico. o Expanded the phase II clinical trial of it's lead antisense drug GTI-2040 for renal cell carcinoma from one to more than six major oncology centers in the U.S.
- Received commitment from the U.S. National Cancer Institute (NCI) to fund an expanded Phase II clinical trial program with GTI-2040. The US FDA has approved the protocol for acute myeloid leukemia, the first of six indications prioritized by the NCI for further clinical development with GTI-2040
- Awarded Orphan Drug status by the U.S. FDA for GTI-2040 for the treatment of advanced renal cell carcinoma
- Signed a letter of intent to conduct a Phase II clinical trial of GTI-2501 for the treatment of advanced metastatic prostate cancer.

Allowed various patents from the U.S., Europe and Mexico to further protect Virulizin(R) "The fiscal year of 2003 has been a year of excellent progress in advancement of clinical and research programs which resulted in the enhancement of fundamental shareholder value", said Dr. Jim Wright, C.E.O. "The successful closing of the recent public offering reflects well on past achievements and the quality of our product portfolio and enhances Lorus' capital position to advance and expand our research and clinical programs toward commercial success."

Net loss for the year ended May 31, 2003 totaled $16,634,000 ($0.12 per share) compared to a loss of $13,487,000 ($0.09 per share) for the previous fiscal year. Operating cash requirements for the year ended May 31, 2003 were $11,908,000, comparable with the previous fiscal year. The increase in net loss relates primarily to more clinical trial activities, partially offset by lower administrative costs and the termination of the amortization of goodwill in accordance with the adoption of a new accounting pronouncement effective June 1, 2002. On a comparable basis, the loss for the year ended May 31, 2002 would have been $12,033,000 or $0.08 per share after adjustment to remove the amortization of goodwill.

Research and development expenses for the year ended May 31, 2003 increased to $12,550,000 from $8,659,000 in the prior year. Cost increases can be attributed mainly to the expansion of the pivotal Phase III Virulizin(R) trial to over 50 North American and Latin American sites; the expansion of the Phase II GTI-2040

combination chemotherapy trial to more than 6 major oncology centers in the US and the preparation for the NCI sponsored GTI-2040 phase II trial programs.

General and administrative expenses for the year ended May 31, 2003 decreased to $4,290,000 compared to $4,867,000 for the previous fiscal year. The decrease was due mainly to lower legal and advisory fees compared to the prior year.

Depreciation and amortization expenses for the year ended May 31, 2003 were $960,000 compared to $1,956,000 in the prior year. The decrease was due mainly to the adoption of the new CICA accounting pronouncement for goodwill and other intangible assets whereby the Company ceased amortizing goodwill on June 1, 2002.

Interest and other income decreased to $1,155,000 for the year ended May 31, 2002 compared to $1,995,000 for the prior year due to lower average cash and short-term investment balances and lower interest rates in 2003.

As at May 31, 2003, Lorus had cash and short-term investments of $25,124,000 compared to $37,822,000 at May 31, 2002. Subsequent to the year end, as a result of the public offering referred to in the highlight section, cash and short-term investments increased by $30,431,000.

CONSOLIDATED STATEMENTS OF LOSS AND DEFICIT
FOR THE YEARS ENDED MAY 31

<TABLE>
<CAPTION>

(Amounts in 000's Canadian dollars except for per common share data)	Year Ended May 31 2003	2002	2001
<S>	<C>	<C>	<C>
REVENUES	$ 66	$ --	$ --
	66	--	--
OPERATING EXPENSES			
Cost of sales	55	--	--
Research and development	12,550	8,659	9,797
General and administrative	4,290	4,867	6,414
Depreciation and amortization	960	1,956	1,903
OPERATING LOSS	17,855	15,482	18,114
INTEREST AND OTHER INCOME	(1,155)	(1,995)	(2,901)
LOSS FOR THE PERIOD	16,634	13,487	15,213
Deficit, beginning of period	74,869	61,382	46,169
DEFICIT, END OF PERIOD	$ 91,503	$ 74,869	$ 61,382
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.12	$ 0.09	$ 0.11
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING USED IN THE CALCULATION OF BASIC AND DILUTED LOSS PER SHARE	144,590	143,480	140,776

</TABLE>

CONSOLIDATED BALANCE SHEETS
AS AT MAY 31

<TABLE>
<CAPTION>

(Amounts in 000's Canadian Dollars)	2003	2002
<S>	<C>	<C>
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	$ 905	$ 1,165
Short-term investments	24,219	36,657
Prepaid expenses and amounts receivable	1,104	1,195
TOTAL CURRENT ASSETS	26,228	39,017
FIXED ASSETS	1,507	533

GOODWILL	606	606
ACQUIRED RESEARCH AND DEVELOPMENT	5,669	7,416
DEFERRED FINANCING COSTS	245	--
	$ 34,255	$ 47,572
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable	$ 1,318	$ 442
Accrued liabilities	4,042	2,990
TOTAL CURRENT LIABILITIES	5,360	3,432
SHAREHOLDERS' EQUITY		
Share capital		
Common shares		
Authorized: unlimited number of shares;		
Issued and outstanding (000's):		
May 31, 2003 - 145,285		
May 31, 2002 - 144,412	120,441	119,168
Deferred stock-based compensation	(43)	(159)
Deficit accumulated during development stage	(91,503)	(74,869)
TOTAL SHAREHOLDERS' EQUITY	28,895	44,140
	$ 34,255	$ 47,572

</TABLE>

Media, members of the financial community and shareholders are invited to listen to Company's quarterly earnings conference call through the live audio webcast on the Company's website at www.lorusthera.com Tuesday, July 22, 2003 at 1:30 p.m. (EST). The conference call webcast will also be archived at www.lorusthera.com.

A telephone replay of the conference call will also be available from approximately 4:00p.m. (EST) Tuesday, July 22, 2003 until 11:59p.m. Monday, July 28, 2003. To access the replay, call 1-877-289-8525 and enter reservation number 21010417#.

About Lorus

Lorus Therapeutics Inc. is a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer. With products in all stages of evaluation, from pre-clinical through Phase III trials, and a product approved in Mexico for malignant melanoma, Lorus is a leader in the development of therapeutics that seek to manage cancer with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC. Corporate Communications Grace Tse Communications Inc. Tel: (416) 798-1200, ext.380 5045 Email:ir@lorusthera.com jennifer@mcipr.com	CANADIAN MEDIA CONTACT: Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	US MEDIA CONTACT: Jennifer Taylor Mansfield Tel: (212) 370- E-mail:

</Table>

LORUS THERAPEUTICS ANNOUNCES THIRD CLINICAL TRIAL WITH GTI-2040 IN COOPERATION WITH THE U.S. NATIONAL CANCER INSTITUTE

-GTI-2040 in combination with docetaxel for the treatment of lung cancer-

TSX: LOR
OTC BB: LORFF

TORONTO, SEPTEMBER 15, 2003 - Lorus Therapeutics announced today that approval has been obtained from Health Canada for initiation of a clinical trial of GTI-2040 in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC), as part of a Phase II clinical program of GTI-2040 in collaboration with the U.S. National Cancer Institute (NCI). The study will be conducted under the direction of Dr. Natasha Leighl at Princess Margaret Hospital in Toronto, a leading clinical and research centre for cancer.

Additional leading oncology centres and investigators participating in this study include the Ottawa Regional Cancer Centre (Dr. Scott Laurie), Hamilton Regional Cancer Centre (Dr. Peter Ellis), and London Regional Cancer Centre (Dr. Mark Vincent).

The study is supported by the Cancer Therapy Evaluation Program (CTEP), an NCI agency that is providing both program coordination and financial sponsorship as part of its mission to support the development of novel anticancer agents.

"Inclusion of lung cancer in the GTI-2040 clinical program in cooperation with the U.S. NCI and leading Canadian oncology clinical research centres is an excellent opportunity to apply our strategy of combining GTI-2040 with established chemotherapeutic regimens without increasing the toxicity profile," said Dr. Jim Wright, chief executive officer, Lorus. "We are pleased to be working with leading oncologists on the development of GTI-2040 in this indication"

Advanced NSCLC, the most common form of lung cancer, is incurable and median survival with current treatments ranges from 8 to 10 months. Based on National Cancer Institute of Canada and American Cancer Society statistics for 2002, it is estimated that 189,000 North Americans will be diagnosed with lung cancer and 173,000 will die from the disease this year.

(more)

While advancements in combination therapies have improved the one year survival rate in lung cancer patients from 25 per cent to greater than 30 per cent, there is a clear need for novel combination treatments to further improve lung cancer outcomes.

Lorus also recently announced the expansion of GTI-2040 into two additional NCI-sponsored studies. One in Acute Myeloid Leukemia is being conduced at Ohio State University Medical Center in Columbus, Ohio under the direction of Dr. Guido Marcucci. Dr. Helen Chew of the University of California Davis Cancer Center is conducting the second study, in advanced breast cancer. The NCI is financially sponsoring this series of Phase II clinical trials to investigate the safety and efficacy of GTI-2040 in six different cancer indications.

GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, a malignant determinant that is elevated in a wide range of tumors and which can cooperate with a variety of other cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. GTI-2040 was chosen for combination with docetaxel, an established agent for treatment of lung cancer, based on preclinical data providing significant activity against NSCLC as a single agent, potential synergy with taxanes in preclinical models, and low toxicity observed as a single agent in a

Phase I clinical trial.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

.
.
.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Inc.
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
jennifer@mcipr.com
</Table>

<C>

CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>

US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
Email:

LORUS THERAPEUTICS TO PRESENT RESULTS OF GENE THERAPY STUDIES AT THE HUPO 2ND ANNUAL & IUBMB XIX JOINT WORLD CONGRESS

- Elevated levels of R1 act as a novel tumor suppressor in experimental models of cancer -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 9, 2003 - Lorus Therapeutics Inc. ("Lorus") will be presenting the results of preclinical studies designed to assess the therapeutic feasibility of R1 gene therapy for treatment of colon cancer at the second annual Human Proteome Organization (HUPO) and International Union of Biochemistry and Molecular Biology XIX (IUBMB) Joint World Congress being held in Montreal, Canada, from October 8-11, 2003.

An abstract prepared by Lorus entitled, "Adenovirus Mediated R1 Tumor Suppressor Gene Therapy Potential Demonstrated in a Human Colon Adenocarcinoma Model" has been accepted for presentation and will also be published in the meeting proceedings.

Lorus will present the results of studies that have demonstrated elevated levels of R1 protein, the large subunit of the ribonucleotide reductase complex, act as a novel tumor suppressor in experimental models of cancer.

"Lorus welcomes the opportunity to present new and exciting research findings at international meetings, and we look forward to receiving valuable feedback from the scientific community," said Dr. Jim Wright, CEO of Lorus.

(more)

In the current study, R1 was incorporated into an adenovirus and delivered to tumor cells by infection. Over-expression of R1 resulted in a dramatic decrease in growth of tumor cells grown in culture. Moreover, tumor cells expressing high levels of R1 did not form tumors when implanted in mice, whereas a non-related gene was not effective in preventing tumor development in mice.

The most notable finding in terms of therapeutic potential was the effectiveness of this approach for TREATING human tumors previously implanted in mice, where very significant decreases in tumor growth were observed. This data was recently published in the October 1 issue of Clinical Cancer Research. Dr. Yun Yen of the Department of Medical Oncology and Therapeutics Research at the City of Hope National Medical Center is a leading researcher on RNR involvement in tumorigenesis and metastasis. He provided an accompanying commentary on the Lorus discovery in the "The Biology Behind" section of the same issue of Clinical Cancer Research, entitled, "Ribonucleotide Reductase Subunit 1 as Gene Therapy Target."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the

OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT
Corporate Communications	Eliza Walsh	Jennifer Taylor
Grace Tse	Mansfield Communications Inc.	Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380	Tel: (416) 599-0024	Tel: (212) 370-5045
Email: ir@lorusthera.com	Email: eliza@mcipr.com	Email: jennifer@mcipr.com

</Table>

LORUS THERAPEUTICS PARTICIPATES IN 11TH ANNUAL BIOPARTNERING EUROPE CONFERENCE IN LONDON, ENGLAND

- Lorus highlights progress of its extensive oncology pipeline -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 14, 2003 - Lorus Therapeutics Inc. ("Lorus") announced that executives from Lorus are presenting a comprehensive review of Lorus' oncology pipeline today between 1:30 p.m. and 4:00 p.m. at the 11th Annual BioPartnering Europe (BPE) conference being held at the Queen Elizabeth II Conference Centre in London, England.

The session will include a presentation of the company's clinical and pre-clinical programs, and highlight the progress Lorus has made in advancing these programs. Currently, Lorus has one phase I clinical trial in the US, four phase II clinical trials in the US and Canada, and a pivotal phase III registration clinical trial in North America and Europe.

BPE provides an opportunity for North American and European biotechnology companies to network and develop new partnerships and is the largest European conference of this kind. It was through the 2001 BioPartnering Europe Conference that Lorus began its discussions with Cyclacel Limited of the UK. These discussions led to the recent exclusive worldwide licensing agreement for the development and commercialization of Lorus' pre-clinical compound NC 381.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market

conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT
Corporate Communications	Eliza Walsh	Jennifer Taylor
Grace Tse	Mansfield Communications Inc.	Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380	Tel: (416) 599-0024	Tel: (212) 370-5045
Email: ir@lorusthera.com	Email: eliza@mcipr.com	Email: jennifer@mcipr.com

</Table>

LORUS PUBLISHES PEER REVIEWED RESULTS OF STUDIES ON THE MECHANISM OF ACTION OF THE ANTI-CANCER DRUG VIRULIZIN(R)

-Company also announces presentation of anti-cancer pipeline at healthcare conference in Boston-

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 22, 2003 - Scientists at Lorus Therapeutics Inc. ("Lorus") have published the results of experimental studies with Virulizin(R), the company's lead anti-cancer drug in the clinic. The results appear in an article entitled, "Macrophages play a critical role in the anti-tumor activity of Virulizin(R)" in the International Journal of Oncology (23: 1341 - 1346, 2003) The publication summarizes the results from studies, which demonstrate that Virulizin(R), a biological response modifier, inhibits tumor growth via stimulation of specific cells of the immune system called macrophages. Studies using cells grown in culture demonstrated that the presence of Virulizin(R) enhanced macrophage-mediated killing of tumor cells. Virulizin(R) treatment was not effective as an anti-tumor agent in mice that were deficient in macrophages, providing strong support of a major role for macrophages in Virulizin(R) mediated anti-tumor activity.

"These studies are exciting because they deepen our understanding of how Virulizin(R) enhances immune responses to a variety of tumor types," said Dr. Jim Wright, CEO of Lorus. "Details of how Virulizin(R) acts, at the cellular level, provide further confirmation of the potent biological activity of the drug and provide valuable information relevant to the clinical development program for Virulizin(R)."

(more)

Virulizin(R) was awarded orphan drug status and fast-track status from the United States Food and Drug Administration in clinical studies for the treatment of pancreatic cancer. The drug is approved in Mexico for the treatment of melanoma and is commercially available in the private market in Mexico through Lorus' marketing partner Mayne Pharma. Virulizin(R) is currently in a Phase III clinical trial in North America and Europe for the treatment of pancreatic cancer in combination with gemcitabine as a first line therapy.

LORUS TO PRESENT AT THE RODMAN & RENSHAW TECHVEST HEALTHCARE CONFERENCE

Lorus also announced that Dr. Jim Wright, CEO of Lorus, will present a comprehensive review of Lorus' oncology pipeline, including studies on the anti-tumor activity of Virulizin(R), today at 8:40 a.m. at the Rodman & Renshaw Techvest Healthcare Conference. The conference is being held from October 21 - 23, 2003 at the Boston Marriott Long Wharf Hotel in Boston, Massachusetts.

The conference brings together institutional investors, venture capitalists, corporate executives, business development officers and scientists to network and investigate different healthcare areas and issues.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the

OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

Draft

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:		
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT
Corporate Communications	Eliza Walsh	Jennifer Taylor
Grace Tse	Mansfield Communications Inc.	Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380	Tel: (416) 599-0024	Tel: (212) 370-5045
Email: ir@lorusthera.com	Email: eliza@mcipr.com	Email: jennifer@mcipr.com

</Table>

LORUS THERAPEUTICS SPONSORS INTERNATIONAL LUNG CANCER SCREENING CONFERENCE
-Lorus to present GTI-2040 studies on lung cancer -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 24, 2003 - Lorus Therapeutics Inc. ("Lorus") will be presenting data on the company's lung cancer research and drug development program at the Ninth International Conference on Screening for Lung Cancer at the University of Miami, Jackson Memorial Hospital, Miami, Florida from October 24-26, 2003. Lorus is a corporate sponsor of the conference and will give a presentation with an abstract entitled "GTI-2040, an antisense oligonucleotide targeting the R2 component of human ribonucleotide reductase, displays broad spectrum anti-tumor activity."

The oral presentation will give a brief overview of recent preclinical and clinical studies of GTI-2040 with a focus on experiments that support the therapeutic application of GTI-2040 for treatment of lung cancer. GTI-2040 decreases the expression of the R2 component of ribonucleotide reductase, an essential enzyme for DNA synthesis, resulting in decreased cell growth and proliferation. Consistent with this model of how GTI-2040 functions, treatment of human lung cancer cells with GTI-2040 specifically decreases R2 expression with a concomitant decrease in cell proliferation. Furthermore, GTI-2040 inhibits the growth of human lung tumors implanted in mice. These results support the expansion of clinical trials to include combinations of GTI-2040 with standard chemotherapeutic drugs for the treatment of lung cancer.

"Lorus is sponsoring this conference because we have a commitment to supporting leading edge research that may translate into a greater understanding of how to diagnose and treat cancer," said Dr. Jim Wright, CEO of Lorus. "Fostering an exchange of information and ideas among researchers is a valuable part of medical research which leads to breakthroughs in understanding disease development and progression. This understanding is an important step towards designing better treatment strategies."

(more)

GTI-2040 is Lorus' lead antisense drug in the clinic, and is currently in multiple Phase II clinical trials including a U.S. National Cancer Institute sponsored trial against non-small cell lung cancer in combination with docetaxel at the Princess Margaret Hospital in Toronto.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES

CONTACTS:

LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com

CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

LORUS THERAPEUTICS INC. - COMPLETION OF UNIT OFFERING

TSE: LOR
OTC BB: LORFF

TORONTO, JUNE 11, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that it had completed its previously-announced best efforts public offering of 22.8 million units priced at $1.25 per unit, for gross proceeds of $28.5 million. In addition, the agents involved in the offering exercised in full their over-allotment option to offer for sale an additional 3.42 million units at an offering price of $1.25 per unit, which raised additional gross proceeds of $4.275 million. Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase a common share at a price of $1.75. As part of the compensation for the offering, the agents received compensation options representing an aggregate of 7% of the units issued pursuant to the offering, which entitle the holder to purchase one unit at an exercise price of $1.27 per unit.

The offering of units of Lorus was completed on a best efforts basis by a syndicate of agents led by Loewen, Ondaatje, McCutcheon Limited that also included Dundee Securities Corporation, Harris Partners Limited and Haywood Securities Inc.

ABOUT LORUS

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

-30-

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES

CONTACTS:

LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com

CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

LORUS THERAPEUTICS INC. FILES FINAL PROSPECTUS FOR $28.5 MILLION OFFERING

TSE: LOR
OTC BB: LORFF

TORONTO, JUNE 4, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that it has filed a final prospectus in each of the provinces of Canada in connection with its previously announced best efforts offering of units at a purchase price of $1.25 per unit. Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase a common share at a price of $1.75.

The size of the offering is 22,800,000 units at a price of $1.25 per unit for gross proceeds of $28.5 million and net proceeds of approximately $26.5 million. Lorus has granted the syndicate of agents led by Loewen, Ondaatje, McCutcheon Limited that also includes Dundee Securities Corporation, Harris Partners Limited and Haywood Securities Inc., an option to offer 3,420,000 additional units at a price of $1.25 per unit to cover over-allotments, which may be exercised for a 30 day period after closing of the offer. Closing is expected on or about June 11 2003. This transaction is subject to certain conditions, including regulatory approval.

ABOUT LORUS

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

(more)

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Inc.
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:
Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
E-mail: jennifer@mcipr.com
</Table>

LORUS THERAPEUTICS INC. FILES PRELIMINARY PROSPECTUS

TSX: LOR
OTC BB: LORFF

TORONTO, MAY 27, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that it has filed a preliminary prospectus in each of the provinces of Canada in connection with its proposed public offering of units. A syndicate of agents will place the units on a best efforts basis.

Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase a common share at a price to be negotiated with the agents. This transaction is subject to certain conditions, including regulatory approval.

The units, the common shares, the warrants and the common shares issuable upon the exercise of the warrants will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which the offer, solicitation or sale would be unlawful.

ABOUT LORUS

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

-30-

.
.
.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS:	
LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications Grace Tse Tel: (416) 798-1200, ext.380 Email: ir@lorusthera.com	Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	Nancy Tamosaitis Mansfield Communications Inc Tel: (212) 370-5045 E-mail: nancyt@mcipr.com

</Table>

LORUS THERAPEUTICS ALLOWED UNITED STATES PATENT TO PROTECT INVENTION OF NOVEL ANTISENSE DRUGS

- Patent protects anticancer drugs -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA - JANUARY 29, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced that the United States Patent and Trademark Office has allowed a patent covering an important component of the company's antisense drug development program that has shown promising anticancer activity in preclinical investigations.

The patent, titled "oligonucleotide sequences complementary to thioredoxin and thioredoxin reductase genes and methods of same to modulate cell growth," protects Lorus' technology on the design and use of unique antisense, anticancer agents that target these specific gene sequences.

"Lorus' lead antisense drugs, GTI-2040 and GTI-2501, which are now in clinical trials, are already protected by issued patents in the U.S.A.," said Dr. Jim A. Wright, chief executive officer, Lorus. "This new patent strengthens and adds significant value to the company's intellectual property portfolio covering its antisense technology."

Thioredoxin and thioredoxin reductase genes have been implicated in tumor formation, tumor progression, and metastasis (spread of tumor cells) by a variety of mechanisms. Reducing the expression of these genes with antisense drugs should interfere with multiple pathways that lead to cancer progression and the inhibition of human tumor growth. Results obtained in studies carried out by Lorus using human tumor cells and mouse models bearing human tumors, support this approach.

(more)

Lorus has chosen lead antisense compounds that have demonstrated excellent antitumor activity in preclinical studies, and these studies are continuing to fully realize the potential of this new approach to the treatment of cancer.

About Lorus
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

<Table>
<Caption>

<S> | <C> | <C>
CONTACTS:
LORUS THERAPEUTICS INC. | CANADIAN MEDIA CONTACT: | US MEDIA CONTACT:

Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

Amy Banek
Mansfield Communications Inc
Tel: (212) 370-5045
E-mail: amy@mcipr.com
</Table>

LORUS THERAPEUTICS ALLOWED UNITED STATES PATENT TO PROTECT KEY ANTISENSE ANTICANCER TARGET

TSE: LOR
OTC BB: LORFF

TORONTO, MARCH 10, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced that the United States Patent and Trademark Office has allowed a patent to protect the company's intellectual property involving a lead anticancer target, the R1 component of ribonucleotide reductase. This patent broadens the protection that Lorus obtained in a patent granted by the United States Patent and Trademark Office in September 2000.

"The two components of ribonucleotide reductase, R1 and R2, are integral to our antisense technology platform and are being used to develop very promising anticancer drugs that are currently in clinical trials," said Dr. Jim Wright, CEO, Lorus Therapeutics Inc. "This patent along with two other patents protecting the R1 and R2 targets already granted in the United States, provide strong and broad protection for a key portion of Lorus's anticancer drug development program, which includes GTI-2040 and GTI-2501, two drugs in clinical trials."

Ribonucleotide reductase is an essential part of the process that converts ribonucleotides to deoxyribonucleotides, which are required for DNA replication and cell proliferation. Inhibition of ribonucleotide reductase by antisense drugs would lead to depletion of the supply of deoxyribonucleotides to tumor cells, and dramatic reduction in tumor growth. GTI-2040 and GTI-2501 are antisense drugs directed at the R2 and R1 subunits of ribonucleotide reductase, respectively.

(more)

GTI-2040, Lorus's most advanced antisense drug, is currently in a phase II clinical trial for the treatment of kidney cancer in combination with capecitabine and is moving into multiple phase II clinical trials for other cancer types.

GTI-2501 is being assessed as a monotherapy in a phase I clinical trial against a variety of advanced cancers. Following successful completion of this clinical trial, Lorus is planning a phase II development strategy to fully investigate the anti-tumor effectiveness of GTI-2501.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other

risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Communications Inc.
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com
jennifer@mcipr.com
</Table>

<C>

CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>

US MEDIA CONTACT:

Jennifer Taylor
Mansfield

Tel: (212) 370-5045
E-mail:

LORUS THERAPEUTICS ALLOWED UNITED STATES PATENT TO PROTECT INVENTION OF NOVEL ANTISENSE ANTIMICROBIAL DRUGS

- Patent protects novel antimicrobial drug development program -

TSE: LOR
OTC BB: LORFF

TORONTO, MAY 13, 2003 - Lorus Therapeutics Inc. ('Lorus') announced today that the United States Patent Office has allowed a patent, which protects the antimicrobial component of the company's antisense drug development program. The patent titled, 'Antisense Oligonucleotide Sequences As Inhibitors of Microorganisms,' protects Lorus' technology on the design and use of unique antisense, antimicrobial agents that target specific gene sequences.

The patent covers the gene targets, SecA and Ribonucleotide reductase (RNR), which are necessary for growth and viability of microorganisms. SecA is an important component of a process required for secretion of bacterial proteins, which is an essential event in the life cycle of pathogenic organisms. RNR is a central enzyme in the formation of components required for DNA synthesis and proliferation. Since the functions of these gene products are needed for survival they are ideal targets for drug development strategies.

"An increasing concern over the appearance of drug resistant microorganisms has led to an increased interest in the development of novel antimicrobial therapeutics" said Dr. Jim A. Wright, chief executive officer, Lorus. "This patent and the one recently allowed in Canada and announced on April 9, 2003, provides protection in North America for an antisense antimicrobial discovery program. It is clear that novel therapeutic agents are required to develop new approaches to deal with life threatening infections that resist conventional treatments."

(more)

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS : LORUS THERAPEUTICS INC.	CANADIAN MEDIA CONTACT:	US MEDIA CONTACT:
Corporate Communications Grace Tse Inc Tel: (416) 798-1200, ext.380 Email: ir@lorusthera.com	Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	Amy Banek Mansfield Communications Tel: (212) 370-5045 E-mail: amy@mcipr.com

</Table>

LORUS ANNOUNCES EXPANSION OF RENAL CELL CARCINOMA CLINICAL TRIAL TO MAJOR ONCOLOGY CENTERS IN THE UNITED STATES

TORONTO FEBRUARY 5, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that it has expanded its ongoing clinical trial of its lead antisense drug, GTI-2040, in renal cell carcinoma to five major oncology centers in the United States (US). The current study is being conducted by Dr. Frank Torti, director of the Comprehensive Cancer Center at Wake Forest University School of Medicine in North Carolina.

Additional investigators and institutions participating in this trial include: Dr. Ronald Bukowski of the Cleveland Clinic Foundation, Dr. Walter Stadler, University of Chicago Medical Center; Dr. Nancy Lewis of Fox Chase Cancer Center in Philadelphia; Dr. Bernard Poiesz of the State University of New York (SUNY) Health Science Center; and Dr. David Quinn of the Norris Comprehensive Cancer Center, University of Southern California.

GTI-2040 is being studied in combination with capecitabine (Xeloda, Roche), for the treatment of advanced renal cell carcinoma in patients who have failed previous chemotherapies. Capecitabine is an oral anticancer treatment that has shown promising response rates in patients with metastatic renal cell carcinoma. The concept and design of the trial was developed by Dr. Walter Stadler of the University of Chicago, who has published extensively in the area of treatments for renal cell carcinoma.

GTI-2040 targets the R2 component of ribonucleotide reductase, a novel malignant determinant that can cooperate with a variety of cancer causing genes, known as oncogenes. Preclinical animal models showed GTI-2040 to have particular efficacy in inhibition of tumor growth in animal tumor models of renal cell carcinoma, alone or in combination with other agents.

(more)

"Renal cell carcinoma is a devastating disease with a high mortality rate, and limited therapeutic options. While immunotherapies have been used with very limited success in a sub-set of patients, serious toxicity with these agents can preclude their therapeutic usefulness. Based on promising preclinical findings, and excellent tolerability in Phase I studies, GTI-2040 offers potential as a new therapy in the treatment of this cancer," said Dr. Walter Stadler of University of Chicago.

"We are very pleased to be expanding this key trial to include internationally recognized oncologists and clinical centers," said Dr. Jim Wright, CEO of Lorus. "This expansion builds on the excellent research of Dr. Frank Torti, and importantly, is a central part of our corporate strategy to develop key networks with oncologists, and to expedite our clinical trial programs. We are pleased to be working with these pre-eminent clinical investigators as we advance GTI-2040 in clinical development."

Renal cell carcinoma is the most common type of kidney cancer with more than 34,000 cases diagnosed annually in North America. The majority of patients are over the age of 40. More than 10,000 patients die annually from this disease in the US, and 100,000 worldwide. The age-adjusted worldwide incidence of renal cell carcinoma has been increasing steadily at an annual rate of approximately two per cent. In advanced metastatic renal cell carcinoma patients, the five-year survival rate is approximately 10 per cent. Current treatments include interferon and interleukin-2 (IL-2). Proleukin, a recombinant form of IL-2 is the only FDA approved drug for the treatment of renal cell carcinoma, however its use is limited by serious toxicity in many patients.

About Lorus
Lorus Therapeutics Inc. is a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer. With products in all stages of evaluation, from pre-clinical through Phase III trials, and a product approved

in Mexico for malignant melanoma, Lorus is a leader in the development of therapeutics that seek to manage cancer with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

-30-

.
.
.

<Table>
<Caption>

<S>	<C>	<C>
CONTACTS: LORUS THERAPEUTICS INC. Corporate Communications Grace Tse Inc. Tel: (416) 798-1200, ext.380 Email:ir@lorusthera.com jennifer@mcipr.com	CANADIAN MEDIA CONTACT: Hugh Mansfield Mansfield Communications Inc. Tel: (416) 599-0024 Email: hugh@mcipr.com	US MEDIA CONTACT: Jennifer Taylor Mansfield Communications Tel: (212) 370-5045 E-mail:

</Table>

LORUS THERAPEUTICS ANNOUNCES EUROPEAN PATENT ALLOWANCE TO PROTECT VIRULIZIN(R)

-European patent allowance protects intellectual property for Virulizin(R) in a strategically important marketplace

TSE: LOR
OTC BB: LORFF

TORONTO, JUNE 24, 2003 - Lorus Therapeutics Inc. ("Lorus") reported today that it has received notice from the European Patent Office of the allowance of a patent, which protects the company's intellectual property for its lead immunotherapeutic anticancer drug, Virulizin(R).

The patent titled, "Immunomodulating Compositions from Bile", specifically protects the composition and use of Virulizin(R) for the treatment of cancer. It is the first Virulizin(R) patent that has been allowed in Europe and adds to the roster of countries that have previously granted Virulizin(R) patents including the United States, Mexico, Canada, Australia, South Africa, New Zealand, Korea and Singapore.

"Although clinical trials with Virulizin(R) are not presently being performed in Europe, Lorus' global development strategy includes expansion into this important market," said Dr. Jim Wright, CEO, Lorus. "As such, we believe that European patent protection is important to Lorus' future marketing strategy."

Virulizin(R) is currently in a pivotal Phase III clinical trial in North and Latin America for the treatment of pancreatic cancer and was awarded orphan drug status and fast track status from the United States Food and Drug Administration in clinical investigations for the treatment of pancreatic cancer. Virulizin is approved in Mexico for the treatment of malignant melanoma and is commercially available in Mexico through Lorus' marketing partner.

(more)

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Inc
Tel: (416) 798-1200, ext.380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:

Jennifer Taylor
Mansfield Communications

Tel: (212) 370-5045
E-mail: jennifer@mcipr.com
</Table>

LORUS THERAPEUTICS ANNOUNCES NEW CLINICAL TRIAL OF GTI-2040 IN ACUTE MYELOID LEUKEMIA IN SPONSORSHIP WITH THE U.S. NATIONAL CANCER INSTITUTE

- Expanding the clinical development of GTI-2040 -

TSE: LOR
OTC BB: LORFF

TORONTO, CANADA, JULY 7, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced the United States Food and Drug Administration's approval of the National Cancer Institute (NCI) sponsored Investigational New Drug (IND) application for a clinical trial of its lead antisense drug, GTI-2040 in combination with cytarabine, in patients with refractory or relapsed acute myeloid leukemia (AML). Cytarabine is the current established drug for treating AML patients.

The new study will be part of a Phase II clinical program to be conducted under the sponsorship of the Division of Cancer Treatment and Diagnosis of the NCI pursuant to a clinical trials agreement between Lorus and the NCI.

The principal investigator, Dr. Guido Marcucci at Ohio State University Medical Center in Columbus, Ohio, selected GTI-2040 for this indication based on positive Phase I clinical data and preclinical data that demonstrated significant anti-tumor activity with GTI-2040 for a wide range of tumors, including lymphoma and leukemia. Of particular interest is the potential complementary mechanism of action of GTI-2040 when combined with cytarabine.

(more)

GTI-2040 targets the R2 component of ribonucleotide reductase, a novel malignant determinant that can cooperate with a variety of cancer causing genes, known as oncogenes, to enhance cancer transformation and malignant potential. R2 is an essential component for the process that supplies deoxyribonucleotides for DNA synthesis and cell division. Down regulation of R2 should lead to a reduced supply of deoxyribonucleotides to tumor cells, and a dramatic inhibition of tumor growth.

Cytarabine, a nucleoside with anti-tumor activity, inhibits DNA polymerases that are important for DNA synthesis and repair. This cytarabine-mediated inhibition would likely increase with inhibition or downregulation of R2, and additionally DNA polymerase inhibition could potentiate the anti-tumor activity of GTI-2040.

AML is one of the most common types of leukemia in the western hemisphere, and even of those patients successfully treated with current therapies, 50 to 80 per cent experience relapse of their cancer. The development of novel targeted combination therapies is an important concept to cancer treatment strategies, and it is believed that this approach is crucial for developing effective new therapeutic treatments for diseases like AML.

"GTI-2040 is currently in a Phase II clinical trial for the treatment of renal (kidney) cell carcinoma in combination with capecitabine," said Dr. Jim Wright, chief executive officer, Lorus. "To now advance this drug into an NCI sponsored clinical trial for AML is a significant accomplishment for expanding the development of GTI-2040. AML is one of six indications prioritized by the NCI for further clinical development with Lorus' GTI-2040, and we look forward to the results of this very promising clinical investigation of a potentially new treatment for AML."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be

used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of

corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

- 30 -

.
.
.

<Table>
<Caption>

<S> <C> <C>
CONTACTS:

LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT:
Corporate Communications Hugh Mansfield Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield
Communications Inc.
Tel: (416) 798-1200, ext.380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email:ir@lorusthera.com Email: hugh@mcipr.com E-mail:
jennifer@mcipr.com
</Table>

LORUS THERAPEUTICS ALLOWED CANADIAN PATENT TO PROTECT NEW ANTICANCER TECHNOLOGY

TSX: LOR
OTC BB: LORFF

TORONTO, JULY 28, 2003 - Lorus Therapeutics Inc. ('Lorus') announced today that the Canadian Patent Office has allowed a patent which protects the company's intellectual property as it relates to the discovery and use of potential antitumor oligonucleotide molecules that target the stability of messenger RNA (mRNA) molecules that code for proteins involved in essential cellular functions.

Two of the genes targeted by this technology, which the company termed "U-sense technology," code for the components of ribonucleotide reductase, a complex which is crucial for the synthesis of DNA and the proliferation of cells, including tumor cells. Since the over-expression of ribonucleotide reductase is important in mechanisms of cancer transformation and disease progression, reducing gene expression through the application of U-Sense molecules has the potential to produce an important new class of anticancer drugs.

"The discovery of this novel approach to designing and developing a potentially new class of anticancer agents, which we believe work through a unique mechanism of action, is evidence of Lorus' strong commitment to discovering new and innovative treatments for devastating diseases like cancer," said Dr. Jim Wright, chief executive officer, Lorus.

(more)

More about the technology:
The U-Sense strategy in drug design is to develop molecules that specifically decrease the level of key proteins that are linked to cancer transformation and disease progression. The expression of proteins in cells is controlled by the stability properties of the mRNA molecules that code for these proteins. Although it is still in the research stage of development, the U-Sense approach is designed to target the stability of mRNA molecules that code for proteins that play an important role in cancer and its progression into highly malignant tumors. By destabilizing the mRNA of a specific cancer related protein, its level may be significantly reduced to provide a novel treatment strategy.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

<Table>
<Caption>

<S> <C> <C>
CONTACTS:

LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Communications Inc.
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com
jennifer@mcipr.com

CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

US MEDIA CONTACT:
Jennifer Taylor
Mansfield

Tel: (212) 370-5045
E-mail:

</Table>

LORUS AND THE U.S. NATIONAL CANCER INSTITUTE GRANTED FDA APPROVAL FOR A PHASE II CLINICAL TRIAL IN BREAST CANCER WITH GTI-2040

- Second clinical trial with NCI sponsorship -

TORONTO, CANADA, August 12, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced that the U.S. Food and Drug Administration ("FDA") has approved the U.S. National Cancer Institute's (NCI) Investigational New Drug Application (IND) to begin a Phase II clinical trial to investigate Lorus' lead antisense drug, GTI-2040, as a treatment for metastatic breast cancer in combination with capecitabine (Xeloda, Roche).

On February 11, 2003, Lorus announced a formal clinical trial agreement between the NCI and Lorus in which the NCI will financially sponsor a series of Phase II clinical trials to investigate the safety and efficacy of GTI-2040 in six different cancer indications, while Lorus will provide the drug. This clinical trial of GTI-2040 in breast cancer is based on positive results obtained in previous preclinical and clinical investigations with the drug, and is the second clinical trial initiation in collaboration with the NCI to be approved by the FDA. The first was a clinical study with GTI-2040 in combination with cytarabine for the treatment of acute myeloid leukemia. GTI-2040 is also in a Phase II clinical trial in the U.S. for the treatment of kidney cancer.

"We are very pleased to advance GTI-2040 into a Phase II clinical trial for breast cancer in cooperation with the U.S. NCI. This achievement marks a significant milestone for Lorus and for the development of this drug." said Dr. Jim Wright, chief executive officer, Lorus. "We believe that new treatment approaches with more effective drugs are essential for managing diseases like breast cancer. Previous studies with GTI-2040 indicate its potential to be used in these treatment strategies, so we are looking forward to the results of this very important clinical investigation."

(more)

Dr. Helen Chew of the University of California Davis Cancer Center will be the lead investigator of this GTI-2040 Phase II clinical trial. A total of three sites: the University of California Davis, the University of Southern California, and the City of Hope, together also known as the California Cancer Consortium, will be participating. Since the California Cancer Consortium's inception, thousands of patients have participated in leading clinical studies sponsored by this group.

Breast cancer is the most common cancer diagnosed in North American women and is the second leading cause of cancer deaths. It is estimated that in 2003, approximately 21,340 new cases of breast cancer will be diagnosed in Canada, while 212,600 new cases of the disease will be diagnosed in the U.S. In the same year, approximately 45,500 men and women in North America will die from breast cancer. Although treatable, metastatic breast cancer is considered incurable with few patients achieving long-term survival with standard chemotherapeutic agents.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

.
.
.

<Table>
<Caption>

<S> <C> <C>
CONTACTS:

LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT:
Corporate Communications Hugh Mansfield Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield
Communications Inc.
Tel: (416) 798-1200, ext.380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email:ir@lorusthera.com Email: hugh@mcipr.com E-mail:
jennifer@mcipr.com
</Table>

LORUS THERAPEUTICS' INTELLECTUAL PROPERTY PORTFOLIO STRENGTHENED BY ALLOWANCE OF A EUROPEAN PATENT TO PROTECT A CLASS OF ANTICANCER AGENTS

TSX: LOR
OTC BB: LORFF

TORONTO, AUGUST 20, 2003 - Lorus Therapeutics Inc. ('Lorus') announced today that one of its subsidiaries, NuChem Pharmaceuticals Inc., through an exclusive license with Harvard University, has been allowed a patent by the European Patent Office. This patent protects the company's intellectual property interests with regard to certain molecules that inhibit cancer progression characterized by abnormal vascularization.

"The protection of our interests in these novel molecules in the European market is essential in a global industry such as ours," said Dr. Jim Wright, chief executive officer, Lorus. "This patent strengthens Lorus' growing intellectual patent portfolio, and complements the company's immunotherapy, antisense, tumor suppressor and U-Sense approaches for designing new anticancer drugs, all of which have recently received patent allowances in major markets."

The patent, entitled "Use of Imidazole for the Treatment of Diseases Characterized by Neovascularization," protects the use of specific small molecules in a class of compounds called imidazoles for the treatment of angiogenic conditions where neovascularization (new blood vessel formation) contributes to the progression of the disease by supplying nourishment to the diseased area. The molecules described in this patent inhibit the growth of cells responsible for neovascularization.

(more)

The invention outlines solid tumors potentially treatable with the molecules described in the patent. For example, they include cancers of the brain, breast, cervix, colon, liver, lung, ovary, pancreas, muscle, skin, testicles, thyroid and kidney.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

<Table>
<Caption>

<S> | <C> | <C>
CONTACTS:
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Communications Inc.
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
jennifer@mcipr.com | CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com | US MEDIA CONTACT
Jennifer Taylor
Mansfield

Tel: (416) 370-5045
Email:
</Table>

LORUS THERAPUETICS ANNOUNCES GLOBAL EXPANSION OF THE VIRULIZIN REGISTRATION PHASE III CLINICAL TRIAL

- Expansion of Phase III clinical trial in advanced pancreatic cancer to Europe and South America -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, SEPTEMBER 30, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today a major global expansion to clinical sites in Europe and South America of its current Phase III clinical trial of Virulizin in advanced pancreatic cancer. The clinical study is now operating at major oncology centres in Russia, Ukraine, and Romania, with additional sites in Poland, the Czech Republic, Hungary, Spain and Brazil in progress. The study is also ongoing at centres in the US, Canada and Mexico. To date, over 100 clinical study sites are involved in this international Phase III clinical trial.

The Virulizin Phase III trial in advanced pancreatic cancer is a multi-centre, double-blind clinical study comparing Virulizin in combination with gemcitabine to gemcitabine and placebo in the first-line treatment setting. The study also includes a second-line treatment component involving Virulizin in combination with 5-FU, versus 5-FU and placebo.

The primary efficacy endpoint of the study is survival. Secondary endpoints in the study include time to treatment progression, which analyzes the effect of Virulizin on key clinical benefit parameters such as pain, analgesic consumption, changes in weight, and performance status.

In addition, the study will also correlate immune parameters with clinical outcome. Virulizin has been associated with increases in natural killer cell activity in an earlier Phase II clinical study, while animal studies have shown similar effects, in addition to stimulation of macrophage activity and associated mediators of the immune response.

(more)

"This is a significant event in the overall clinical development program for Virulizin. Expansion of this study to international oncology centres throughout Europe and Brazil has been a long-standing strategy for Lorus to ensure we remain successfully on track with key milestones in our trial program," said Dr. Jim Wright, CEO of Lorus. "This strategy also benefits Lorus' future commercial interests, as global trials optimize awareness of Virulizin among oncologists worldwide, well before a commercial launch. Such early awareness is essential to any successful pharmaceutical marketing strategy."

Virulizin has been shown to be a well-tolerated oncology drug with low toxicity in both pre-clinical and clinical studies. The company received FDA fast-track designation for Virulizin in the treatment of advanced pancreatic cancer in 2002, and orphan drug status in the US for the same indication in 2001. Virulizin is currently marketed in Mexico for malignant melanoma as part of an exclusive distribution agreement with Mayne Pharma for Mexico. Under the terms of the agreement, Lorus receives royalties from the sales of Virulizin(R) and is responsible for manufacturing the drug. Mayne Pharma recently exercised its option for similar agreements in Brazil and Argentina. Lorus also supplies Virulizin through emergency drug and compassionate-use programs around the world to patients with advanced pancreatic cancer and other cancers.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of

cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

<Table>
<Caption>

<S>
CONTACTS:
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Communications Inc.
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com
Email:jennifer@mcipr.com
</Table>

<C>
CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.

Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield

Tel: (212) 370-5045

LORUS THERAPEUTICS PUBLISHES RESULTS OF NOVEL GENE THERAPY APPROACH FOR COLON CANCER

- Tumor suppression of colon cancer in pre-clinical tests -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 1, 2003 - Scientists at Lorus Therapeutics Inc. ("Lorus") have published the results of experimental studies aimed at developing an anti-cancer gene therapy based on over-expression of a novel tumor suppressor gene in colon cancer cells. The results appear in an article entitled, "Adenovirus-mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma" in the October 1 issue (Volume 9, issue 12, page 4553-4561) of Clinical Cancer Research.

The publication presents the results from studies demonstrating that the large subunit of ribonucleotide reductase (RNR), R1, acts as a novel tumor suppressor that, as a gene therapy, has the potential to treat colon cancer.

A virally encoded human R1 gene was delivered into tumor cells by infection resulting in high expression levels of the R1 protein. Over-expression of R1 decreased tumor cell growth in a number of colon cancer cell lines in culture. Furthermore, pre-treatment of colon cancer cells with a recombinant virus encoding R1 resulted in decreased growth of tumors after implantation of the treated cells into mice.

(more)

Most importantly, a dramatic and sustained decrease in tumor growth resulted when human colon tumors implanted into mice were directly injected once a day for a total of five times, with a recombinant virus encoding R1, suggesting the treatment is clinically feasible. The anti-tumor activity was specific to expression of the R1 gene as evidenced by the superior efficacy over the same virus encoding a gene other than R1.

"The expansion of Lorus' research to include development of a viral-based gene therapy demonstrates our commitment to the discovery of novel cancer therapies. Publication in a highly regarded scientific journal, such as Clinical Cancer Research, adds confidence to both our scientific capabilities and to our approach to drug discovery and development," said Dr. Jim Wright, CEO of Lorus.

Dr. Yun Yen from the Department of Medical Oncology & Therapeutics Research at the City of Hope National Medical Center is a leading researcher on RNR involvement in tumorigenesis and metastasis and provides a commentary on the Lorus discovery in the "The Biology Behind" section of the same issue of Clinical Cancer Research (page 4304-4308), entitled, "Ribonucleotide Reductase Subunit 1 as Gene Therapy Target."

Dr. Yen summarizes the current understanding of how R1 functions in cell proliferation and DNA damage repair. Moreover, he outlines the implications of the results of the Lorus study to our understanding of the mechanisms by which R1 contributes to the above processes and the potential application of R1 gene therapy in cancer treatment.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be

used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

.
.
.

<TABLE>
<S> <C> <C>

CONTACTS:
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com
</TABLE>

LORUS THERAPEUTICS PRESENTS AT CANADA'S LEADING BIOPHARMACEUTICAL SYMPOSIUM IN QUEBEC CITY

-Lorus reviews progress of its extensive oncology pipeline-

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 3, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that Dr. Jim Wright, CEO of Lorus, will present a comprehensive review of Lorus' oncology pipeline this morning at 10:00 a.m. at BioContact Quebec 2003, Canada's leading biopharmaceutical conference.

The presentation will include a discussion of the company's research and pre-clinical programs, and highlight the significant progress Lorus has made in the clinical programs with six clinical trials of three different anticancer drugs currently underway in North America.

The BioContact conference provides a forum for participants in the global biotechnology industry to network and meet with representatives from major biopharmaceutical companies from across North America, Europe and Asia.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:
Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com
</TABLE>

LORUS TO PRESENT RESULTS OF STUDIES WITH GTI-2040 IN BREAST CANCER MODELS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH SPECIAL CONFERENCE

- Cooperative anti-tumor activity observed in combination with standard chemotherapy agents -

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, OCTOBER 8, 2003 - Lorus Therapeutics Inc. ("Lorus") will be presenting the results of preclinical studies aimed at assessing the potential therapeutic application of GTI-2040 for the treatment of breast cancer at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Breast Cancer Research; Genetics, Biology, and Clinical Implications, which will be held in Huntington Beach, California from October 8-12, 2003.

An abstract prepared by Lorus entitled "GTI-2040, An Antisense Oligonucleotide Targeting the R2 Component of Human Ribonucleotide Reductase Displays Cooperative Anti-tumor Activity when Combined with Standard Chemotherapeutic Drugs in Murine Models of Human Breast Cancer" has been accepted for presentation and will be published in the meeting proceedings.

Lorus will present the results of studies that examined the effects of combining GTI-2040 treatment with standard chemotherapeutic compounds including doxorubicin, cisplatin and taxol. The anti-tumor activity of all the tested combinations exceeded treatment with the single agents. Previous studies have demonstrated that GTI-2040, as a single agent, has excellent anti-tumor properties against human breast tumors implanted in mice.

(more)

In addition, GTI-2040 treatment resulted in excellent anti-tumor activity against chemotherapy-resistant human breast tumors implanted in mice. Again, combinations with standard drugs, to which the tumors were sensitive, demonstrated cooperative anti-tumor activity with GTI-2040.

The results of these studies support the application of GTI-2040 to a number of currently available treatments for breast cancer. Most importantly, these studies demonstrate that GTI-2040 has the potential to act when patients develop drug resistance, an event that is responsible for a large percentage of treatment failures.

"Lorus is committed to advancing antisense drug candidates through clinical trials, and our research team continues to expand our understanding of the potential applications for GTI-2040. These studies have greatly contributed to Lorus' success in obtaining clinical trial support from institutions such as the US National Cancer Institute (NCI) and provide a solid scientific basis for directing drug development," said Dr. Jim Wright, CEO of Lorus.

GTI-2040 is Lorus' lead antisense drug and is currently in multiple Phase II clinical trials, including an NCI sponsored trial against metastatic breast cancer in combination with capecitabine.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public

company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

.
.
.

CONTACTS:

<TABLE>

<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com
</TABLE>

LORUS THERAPEUTICS SUPPORTS PANCREATIC CANCER AWARENESS MONTH

-Update of Virulizin(R) compassionate use program announced-

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, NOVEMBER 7, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today the further global expansion of the compassionate use program for Virulizin(R), its lead Phase III clinical drug for advanced pancreatic cancer. The program has grown to include a total of 10 countries, with over 60 patients having received Virulizin(R)for treatment of advanced pancreatic cancer in the past year. Countries that have granted regulatory authorization for use of Virulizin(R) as a compassionate drug now include the US, Canada, Japan, Australia, Italy, Israel, Greece, Cyprus, Korea, and Taiwan.

"We are pleased to be able to support pancreatic cancer patients and health-care providers worldwide in their efforts to seek newer, less toxic treatments. The requests we receive through our program from patients and physicians in countries around the globe attests to the dire need for new treatments," said Dr. Jim Wright, CEO of Lorus. "We see a large demand for supply of this drug, and our staff are committed to making as much supply as possible available to compassionate use patients."

Since re-launching the compassionate use program in 2002, Lorus has provided Virulizin(R) to patients primarily following failure of mainstay therapy, or in the first-line setting where less toxic therapeutic alternatives were required. Compassionate use data is being collected by Lorus and will be included as part of the safety and use database for regulatory dossier filings. Compassionate use programs are available in many countries to enable patients, following health authority authorization, to receive investigational drugs or foreign-approved drugs for the treatment of serious illnesses where no suitable alternative treatment exists.

(more)

In addition, the company also announced as part of its commitment to Pancreatic Cancer Awareness Month, its participation in the Weekend of Hope: Pancreatic Cancer Symposium being held on November 7-9, 2003 in California. This patient-based symposium is presented by the Pancreatic Cancer Action Network (PanCAN), a national non-profit, patient advocacy organization that serves the pancreatic cancer community.

"PanCAN is an important patient-oriented organization dedicated to helping pancreatic cancer patients," added Dr. Wright. "We support its initiatives to educate people about pancreatic cancer, as we evaluate Virulizin(R), in a Phase III clinical trial for advanced pancreatic cancer at over 100 oncology centres worldwide."

About Virulizin(R)
Virulizin(R) is currently in a global Phase III clinical trial for advanced pancreatic cancer at major oncology centers in the US, Canada, Eastern and Central Europe, and Latin America. The Phase III clinical study examines the use of Virulizin(R) in the first-line treatment setting, in combination with gemcitabine, the current chemotherapeutic standard of care for advanced pancreatic cancer. Virulizin(R) is an immunotherapeutic drug that has been shown to be well-tolerated in clinical trials. The drug has also demonstrated a broad range of anti-tumor efficacy in pre-clinical testing. Virulizin(R) is currently marketed in Mexico for malignant melanoma under a distribution agreement with Mayne Pharma.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical,

clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

<C>
CANADIAN MEDIA CONTACT:
Eliza Walsh
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: eliza@mcipr.com

<C>
US MEDIA CONTACT
Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
Email: jennifer@mcipr.com
</TABLE>

LORUS THERAPEUTICS PRESENTS AT BIO-EUROPE INTERNATIONAL PARTNERING CONFERENCE

-Lorus also presents to German companies through Canadian sponsored event-

TSX: LOR
OTC BB: LORFF

TORONTO, CANADA, NOVEMBER 18, 2003 - Lorus Therapeutics Inc. ("Lorus") announced today that Lorus will present a review of its oncology pipeline at 2:15 p.m. on Tuesday, November 18, 2003 at Bio-Europe 2003 in Frankfurt, Germany.

Bruce Rowlands, senior advisor, will give a presentation that will highlight the company's clinical programs, and outline the significant progress Lorus has made during the past year. Currently, Lorus has one Phase I clinical trial in the US, four Phase II clinical trials in the US and Canada, and a pivotal Phase III registration clinical trial in pancreatic cancer in North America and Europe.

Lorus will also be participating in the Canadian government sponsored partnering meeting, which presents Canadian biotechnology companies to German pharmaceutical companies to facilitate international partnership opportunities. Seventeen Canadian companies will be participating, including Lorus.

The annual Bio-Europe Conference provides a forum where international representatives in the biotechnology, pharmaceutical, and financial sector can meet to initiate and develop partnerships. The success of Bio-Europe is based on three major components: partnering, presentations, and expert workshops and panels.

(more)

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Forward Looking Statements
Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

.
.
.

CONTACTS:

<TABLE>

<S>
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
Email:ir@lorusthera.com
</TABLE>

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
Email: hugh@mcipr.com

<C>
US MEDIA CONTACT:

Jennifer Taylor
Mansfield Communications Inc.
Tel: (212) 370-5045
E-mail: jennifer@mcipr.com

TSX: LOR
OTCBB: LORFF

LORUS THERAPEUTICS REPORTS FIRST QUARTER RESULTS FOR FISCAL YEAR 2004

TORONTO, CANADA - OCTOBER 10, 2003 - Lorus Therapeutics Inc. ("Lorus") today reported financial results for the quarter ended August 31, 2003. Unless specified otherwise, all amounts are in Canadian dollars.

JUNE 1, 2003 TO DATE HIGHLIGHTS

- Raised net proceeds of approximately $30 million by way of a public offering of units at a price of $1.25 per unit with each unit consisting of one common share and one-half of one purchase warrant.

- Expanded the pivotal phase III clinical trial of its lead immunotherapeutic drug Virulizin(R) for the treatment of advanced pancreatic cancer to over 100 global sites covering Europe, North America, South America and Latin America

- Entered into a worldwide exclusive out-licensing agreement with Cyclacel Limited of the UK for NC381 and a library of clotrimazole analogs for an upfront fee of US$0.4 million with potential of up to approximate US$11.6 million of milestone payments if all milestones achieved and a royalty line on future sales for NC381. Similar milestone and royalty payments will be received for each of any other compounds developed from the library

- Initiated three of the six clinical trials of a phase II clinical program of GTI-2040 in collaboration with the US National Cancer Institute (NCI) the first for patients with Acute Myeloid Leukemia (AML); a second for patients with metastatic breast cancer and a third for patients with non-small cell lung cancer.

- Allowed various patents from U.S., Canada and Europe to further protect Lorus' intellectual properties including Virulizin(R) , "U-sense", a novel anticancer technology and certain molecules that inhibit cancer progression characterized by abnormal vascularization

- Published various papers by Lorus scientists in prominent scientific journals and made presentations at some of the most influential gatherings and meetings in the cancer research field.

"We continue to build momentum in enhancing shareholder values by focusing on the strategic objectives. Out-licensing of NuChem NC381 and a library of clotrimazole analogs facilitates the further development of this technology with a world-class expert while allowing Lorus to focus its resources on its advanced clinical programs and other promising preclinical technologies," said Dr. Jim Wright, C.E.O,

"And the successful closing of the recent public offering enhanced our capital position, enabled us to continue to advance and expand our research and clinical programs and strategically positioned us well for ultimate commercial success."

Net loss for the quarter ended August 31, 2003 totaled $8,171,000 ($0.05 per share) compared to a loss of $4,076,000 ($0.03 per share) for the same quarter last year. The increase in net loss relates primarily to higher research and development expenses.

Research and development expenses for the quarter ended August 31, 2003 increased to $7,263,000 compared to $3,047,000 for the same quarter last year. The cost increase in fiscal 2004 can be attributed primarily to higher clinical trial costs for the expansion of the pivotal Phase III trial of Virulizin(R) for the treatment of advanced pancreatic cancer to over 100 worldwide sites, the upfront supplying of GTI-2040 drug to the NCI for the NCI sponsored phase II clinical trial programs and the expanded GTI-2040 phase II trial in patients with renal cell carcinoma.

General and administrative expenses for the first quarter of fiscal 2004 remained relatively unchanged year over year with a marginal decrease of $73,000.

Depreciation and amortization for the first quarter of fiscal 2004 was $99,000, comparable with $95,000 for the same quarter last year.

Interest income for the quarter ended August 31, 2003 increased to $393,000 from $370,000 for the same quarter last year. The increase can be attributed primarily to higher cash and short-term investment balance partially offset by lower market interest rates in fiscal 2004.

At August 31, 2003 Lorus had cash and cash equivalents and short-term investments totaling $49.0 million compared to $25.1 million at May 31, 2003. Working capital was $43.0 million at August 31, 2003 compared to $20.9 million at May 31, 2003.

CONSOLIDATED STATEMENTS OF LOSS AND DEFICIT (UNAUDITED)

<TABLE>
<CAPTION>

(Amounts in 000's except for per common share data) (Canadian Dollars)	THREE MONTHS ENDED AUG. 31, 2003	Three months ended Aug. 31, 2002	Period from inception Sept. 5, 1986 to Aug. 31, 2003
<S>	<C>	<C>	<C>
REVENUES	$ 29	$ --	$ 95
	29	--	95
EXPENSES			
Cost of Sales	--	--	55
Research and development	7,263	3,047	66,322
General and administrative	1,231	1,304	34,109
Depreciation and amortization	99	95	8,460
OPERATING EXPENSES	8,593	4,446	108,946
INTEREST AND OTHER INCOME	(393)	(370)	(9,177
LOSS FOR THE PERIOD	8,171	4,076	99,674

</TABLE>

<TABLE>
<CAPTION>

(Amounts in 000's except for per common share data) (Canadian Dollars)	THREE MONTHS ENDED AUG. 31, 2003	Three months ended Aug. 31, 2002	Period from inception Sept. 5, 1986 to Aug. 31, 2003
<S>	<C>	<C>	<C>
Deficit, beginning of period	91,503	74,869	--
DEFICIT, END OF PERIOD	$ 99,674	$ 78,945	$ 99,674

</TABLE>

BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.05	$ 0.03
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING USED IN THE CALCULATION OF BASIC AND DILUTED LOSS PER SHARE ..	171,517	144,416

</TABLE>

As Lorus is having its Annual General Meeting of the shareholders on November 20, we will not hold a conference call to discuss the operating results of this quarter. Lorus always welcomes the shareholders, the financial community and the general public to contact us at any time.

About Lorus
Lorus Therapeutics Inc. is a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer. With products in all stages of evaluation, from pre-clinical through Phase III trials, and a product approved in Mexico for malignant melanoma, Lorus is a leader in the development of therapeutics that seek to manage cancer with efficacious non-toxic compounds that improve patients' quality of life. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.

.
.
.

CONTACTS:

<TABLE>
<S>
LORUS THERAPEUTICS INC.

Corporate Communications
Grace Tse
Tel: (416) 798-1200, ext.380
EMAIL: IR@LORUSTHERA.COM

<C>
CANADIAN MEDIA CONTACT:

Hugh Mansfield
Mansfield Communications Inc.
Tel: (416) 599-0024
EMAIL: HUGH@MCIPR.COM

<C>
US MEDIA CONTACT:

Nancy Tamosaitis
Mansfield Communications Inc
Tel: (212) 370-5045
E-MAIL: NANCYT@MCIPR.COM
</TABLE>

LORUS THERAPEUTICS PARTICIPATES AT THE THIRTY-NINTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

TSX: LOR

OTC BB: LORFF

TORONTO, CANADA, JUNE 2, 2003 - Lorus Therapeutics Inc. ("Locus") announced today that data concerning two of its lead drugs, GTI-2040 and Virulizin(R) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), May 31" to June 3 degrees degrees 2003, in Chicago, Illinois.

GTI-2040 will be the subject of a presentation today co-authored by clinicians and scientists from the University of Chicago and Lorus, entitled, "A Phase I study of G77--2040 given by continuous intravenous infusion inpatients with advanced malignancies." The presentation will provide an overview of the safety, tolerability and pharmacoldnetics from a Phase I clinical trial conducted in a variety of tumour types. -The data from this study was used in the design of a Phase B clinical trial with GTI-2040 for the treatment of renal cell carcinoma, which is currently in progress at 10 major oncology centres in the United States.

VirufzinV, Lorus' lead immunothempy drug currently in a North American Phase III clinical trial for the treatment of advanced metastatic pancreatic cancer, is the subject of an abstract co-authored by scientists at Lorus entitled, "Virulizin(R), a novel immunotherapeutic agent stimulates Natural Killer (NW) cell function in implanted human tumors -potential biologic marker of clinical response ". A data presentation of the Virulizin(R) study performed in animal models will be given at the Lorus exhibitor booth at the meeting, where Lorus will also present the clinical trials programs for its three drugs currently in the clinic: VimlizinV, GTI-2040, and GTI-2501. GTI-2501 is in a Phase I clinical trial for the treatment of a variety of solid tumors and Lorus intends to commence a Phase II clinical trial with GTI-2501 for the treatment of advanced metastatic prostate cancer later this year.

(more)

The ASCO annual conference is an important event in clinical oncology worldwide, attracting researchers, clinicians and members of the pharmaceutical industry. The conference provides oncology professionals with the most current information on recent developments in cancer research, prevention, and treatment.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOP, and on the OTC BB exchange under the symbol LOPFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions,

the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.